[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 247
1. Milner R, Hung S, Erokwu B, Dore-Duffy P, LaManna JC, del Zoppo GJ: Increased expression of fibronectin and the alpha 5 beta 1 integrin in angiogenic cerebral blood vessels of mice subject to hypobaric hypoxia. Mol Cell Neurosci; 2008 May;38(1):43-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of fibronectin and the alpha 5 beta 1 integrin in angiogenic cerebral blood vessels of mice subject to hypobaric hypoxia.
  • We showed previously that angiogenic capillaries in the developing CNS express high levels of fibronectin and its receptor alpha5beta1 integrin, and that this expression is developmentally downregulated.
  • As cerebral hypoxia leads to an angiogenic response, we sought to determine whether angiogenic vessels in the adult CNS re-express fibronectin and the alpha5beta1 integrin.
  • Immunofluorescent studies demonstrated that the alpha5 integrin was expressed by angiogenic endothelial cells.
  • In light of the defined angiogenic role for fibronectin in other systems, this work suggests that induction of fibronectin-alpha5beta1 integrin expression may be an important molecular switch driving angiogenesis in the hypoxic CNS.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1982 Nov;79(5):269-76 [6752289.001]
  • [Cites] J Comp Neurol. 1985 Nov 8;241(2):237-49 [4067017.001]
  • [Cites] J Invest Dermatol. 1985 Dec;85(6):564-8 [3934289.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167-71 [2424019.001]
  • [Cites] Dev Biol. 1988 Feb;125(2):441-50 [3338622.001]
  • [Cites] Lab Invest. 1988 Jul;59(1):44-51 [2455830.001]
  • [Cites] Tissue Cell. 1988;20(2):193-209 [3406938.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;58(3):207-13 [1970682.001]
  • [Cites] Semin Cancer Biol. 1992 Apr;3(2):57-63 [1378310.001]
  • [Cites] J Appl Physiol (1985). 1992 Jun;72(6):2238-43 [1629078.001]
  • [Cites] Mol Reprod Dev. 1992 Jun;32(2):121-6 [1637550.001]
  • [Cites] Cell. 1993 Mar 26;72(6):835-46 [7681362.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10061-5 [7694279.001]
  • [Cites] Development. 1993 Dec;119(4):1079-91 [8306876.001]
  • [Cites] J Neurochem. 2006 Jan;96(1):148-59 [16269008.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2006 Apr;290(4):R1105-14 [16322350.001]
  • [Cites] Adv Exp Med Biol. 2006;588:171-88 [17089889.001]
  • [Cites] Mol Cell Neurosci. 2006 Dec;33(4):429-40 [17049262.001]
  • [Cites] J Immunol. 2007 Jun 15;178(12):8158-67 [17548654.001]
  • [Cites] Stroke. 2008 Jan;39(1):191-7 [18032737.001]
  • [Cites] Exp Physiol. 2002 May;87(3):373-81 [12089605.001]
  • [Cites] J Appl Physiol (1985). 2002 Sep;93(3):1131-9 [12183511.001]
  • [Cites] Mol Cell Neurosci. 2002 Aug;20(4):616-26 [12213443.001]
  • [Cites] Stroke. 2002 Dec;33(12):2985-91 [12468801.001]
  • [Cites] Microsc Res Tech. 2003 Jan 1;60(1):13-22 [12500256.001]
  • [Cites] J Cereb Blood Flow Metab. 2003 Feb;23(2):166-80 [12571448.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9022-9 [14663480.001]
  • [Cites] Cancer Treat Res. 2004;117:263-84 [15015565.001]
  • [Cites] Brain Res Brain Res Rev. 2004 Jul;45(3):143-63 [15210301.001]
  • [Cites] Stroke. 2004 Jul;35(7):1732-7 [15178821.001]
  • [Cites] J Exp Biol. 2004 Aug;207(Pt 18):3163-9 [15299038.001]
  • [Cites] Acta Neuropathol. 1971;18(4):273-85 [4999175.001]
  • [Cites] J Exp Med. 1982 Aug 1;156(2):646-51 [7047672.001]
  • [Cites] Development. 1993 Dec;119(4):1093-105 [7508365.001]
  • [Cites] J Neuroimmunol. 1994 May;51(2):199-208 [7514186.001]
  • [Cites] Stroke. 1994 Aug;25(8):1651-7 [7518971.001]
  • [Cites] Stroke. 1994 Sep;25(9):1794-8 [7521076.001]
  • [Cites] Brain Pathol. 1994 Jul;4(3):207-18 [7524960.001]
  • [Cites] Int J Cancer. 1994 Dec 1;59(5):612-8 [7525495.001]
  • [Cites] J Cell Sci. 1994 Sep;107 ( Pt 9):2499-508 [7844167.001]
  • [Cites] Development. 1995 Feb;121(2):549-60 [7539359.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):70-4 [7596437.001]
  • [Cites] Dev Dyn. 1995 Apr;202(4):325-32 [7626790.001]
  • [Cites] Glia. 1995 Nov;15(3):339-47 [8586468.001]
  • [Cites] Nature. 1996 Apr 4;380(6573):439-42 [8602242.001]
  • [Cites] Stroke. 1996 May;27(5):852-7 [8623105.001]
  • [Cites] Neurosurgery. 1996 May;38(5):915-24; discussion 924-5 [8727816.001]
  • [Cites] Chem Biol. 1996 Nov;3(11):881-5 [8939711.001]
  • [Cites] EXS. 1997;79:159-92 [9002232.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Nat Biotechnol. 1997 Nov;15(12):1271-5 [9359110.001]
  • [Cites] Glia. 1998 Dec;24(4):437-48 [9814824.001]
  • [Cites] Cell. 1998 Nov 13;95(4):507-19 [9827803.001]
  • [Cites] J Appl Physiol (1985). 1999 Jan;86(1):260-4 [9887138.001]
  • [Cites] Adv Exp Med Biol. 1998;454:287-93 [9889903.001]
  • [Cites] J Cereb Blood Flow Metab. 1999 Dec;19(12):1345-53 [10598939.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1345-62 [10751360.001]
  • [Cites] Ann N Y Acad Sci. 2000 Apr;903:335-44 [10818523.001]
  • [Cites] J Appl Physiol (1985). 2000 Nov;89(5):1937-42 [11053346.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33920-8 [10944524.001]
  • [Cites] J Mol Cell Cardiol. 2001 Feb;33(2):283-94 [11162133.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):359-67; discussion 367-8 [11220380.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5255-61 [11431367.001]
  • [Cites] Curr Opin Cell Biol. 2001 Oct;13(5):563-8 [11544024.001]
  • [Cites] Stroke. 2001 Sep;32(9):2179-84 [11546914.001]
  • [Cites] J Mol Cell Cardiol. 2002 Mar;34(3):335-48 [11945025.001]
  • [Cites] Development. 2002 Jun;129(12):2891-903 [12050137.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Jun 1;22(6):927-33 [12067900.001]
  • [Cites] Microvasc Res. 1999 Mar;57(2):75-85 [10049655.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Apr;58(4):313-20 [10218626.001]
  • (PMID = 18343155.001).
  • [ISSN] 1095-9327
  • [Journal-full-title] Molecular and cellular neurosciences
  • [ISO-abbreviation] Mol. Cell. Neurosci.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R37 NS038710-08; United States / NINDS NIH HHS / NS / NS143627; United States / NIAID NIH HHS / AI / R01 AI043627-01A1; United States / PHS HHS / / NSO53716; United States / NINDS NIH HHS / NS / NS038632-01A1; United States / NINDS NIH HHS / NS / R01 NS038632; United States / NINDS NIH HHS / NS / R01 NS053716-01; United States / NINDS NIH HHS / NS / R37 NS038710; United States / NINDS NIH HHS / NS / NS047672; United States / NINDS NIH HHS / NS / R01 NS053716; United States / NINDS NIH HHS / NS / NS38632; United States / NINDS NIH HHS / NS / NS053716-01; United States / NINDS NIH HHS / NS / NS038710-08; United States / NINDS NIH HHS / NS / NS053716-04; United States / NINDS NIH HHS / NS / NS047672-01; United States / NINDS NIH HHS / NS / R01 NS047672; United States / NINDS NIH HHS / NS / R01 NS038632-01A1; United States / NINDS NIH HHS / NS / R01 NS053716-04; United States / NINDS NIH HHS / NS / R01 NS047672-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibronectins; 0 / Integrin alpha5beta1
  • [Other-IDs] NLM/ NIHMS78778; NLM/ PMC2588547
  •  go-up   go-down


2. Maruyama Y, Ono M, Kawahara A, Yokoyama T, Basaki Y, Kage M, Aoyagi S, Kinoshita H, Kuwano M: Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res; 2006 Jun 15;66(12):6233-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cellular expression of matrix metalloproteinase-9 and two major angiogenic factors, vascular endothelial growth factor and interleukin-8, were also significantly decreased in cell lines with Cap43 overexpression as compared with their parental counterparts.
  • Thus, Cap43 could play a key role in the angiogenic on- or off-switch of tumor stroma in pancreatic ductal adenocarcinoma.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778198.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Interleukin-8; 0 / Intracellular Signaling Peptides and Proteins; 0 / N-myc downstream-regulated gene 1 protein; 0 / Proteins; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


3. Merdzhanova G, Gout S, Keramidas M, Edmond V, Coll JL, Brambilla C, Brambilla E, Gazzeri S, Eymin B: The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene; 2010 Sep 30;29(39):5392-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.
  • Besides being regulated by transcription, VEGF-A is also highly regulated by pre-mRNA alternative splicing, resulting in the expression of several VEGF isoforms with either pro-(VEGF(xxx)) or anti-(VEGF(xxx)b) angiogenic properties.
  • We further show that, strikingly, E2F1 alters the ratio of pro-VEGF(xxx) versus anti-VEGF(xxx)b angiogenic isoforms, favouring the antiangiogenic isoforms, by a mechanism involving the induction of SC35 expression.
  • Overall, these findings highlight E2F1 and SC35 as two regulators of the VEGF(xxx)/VEGF(xxx)b angiogenic switch in human cancer cells, a role that could be crucial during tumour progression, as well as in tumour response to antiangiogenic therapies.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20639906.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / E2F1 Transcription Factor; 0 / E2F1 protein, human; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / Proteins; 0 / RNA Precursors; 0 / RNA, Messenger; 0 / Ribonucleoproteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 147153-65-9 / SRSF2 protein, human
  •  go-up   go-down


Advertisement
4. Ribatti D: Endogenous inhibitors of angiogenesis: a historical review. Leuk Res; 2009 May;33(5):638-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In pathological states such as chronic inflammation and tumor growth, there is an imbalance between endogenous stimulator and inhibitor levels, leading to an "angiogenic switch".

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19117606.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 97
  •  go-up   go-down


5. Elice F, Rodeghiero F, Falanga A, Rickles FR: Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol; 2009 Mar;22(1):115-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five anti-angiogenic agents (thalidomide, lenalidomide, bevacizumab, sunitinib, sorafenib) have already obtained US Food and Drug Administration approval for clinical use, and many others have entered clinical trials.
  • Many new biological agents with anti-angiogenic properties appear to be associated with an increased risk for thrombosis and, paradoxically, bleeding.
  • Although the mechanisms underlying the increased thromboembolic risk remain ill defined, the main hypothesis is that perturbation of tumour-associated endothelial cells can switch the endothelium from a naturally anticoagulant surface to a prothrombotic surface, thus mediating the activation of systemic coagulation in cancer patients, who are already more susceptible to thromboembolism due to their underlying disease.
  • The toxicity profile differs between the anti-angiogenic agents.
  • The observation of these vascular toxicities suggests the need to establish, in randomized clinical trials, the usefulness of thrombosis prophylaxis when anti-angiogenic agents are used in cancer patients, especially when associated with chemotherapy.
  • In addition, careful reporting of haemostatic complications during treatment with new anti-angiogenic drugs is warranted.

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19285278.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  • [Number-of-references] 100
  •  go-up   go-down


6. Edelmann J, Klein-Hitpass L, Carpinteiro A, Führer A, Sellmann L, Stilgenbauer S, Dührsen U, Dürig J: Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk Res; 2008 Oct;32(10):1565-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells.
  • STR as compared to TW conditions induced a significant up-regulation of PI3K/NF-kappaB pro-survival pathway genes and mediated a pro-angiogenetic switch in the CLL cells by up-regulation of vascular endothelial growth factor (VEGF) and osteopontin (OPN) and down-regulation of the anti-angiogenetic molecule thrombospondin-1 (TSP-1).
  • [MeSH-major] Angiogenic Proteins / metabolism. Fibroblasts / physiology. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. NF-kappa B / metabolism. Phosphatidylinositol 3-Kinases / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18407351.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / NF-kappa B; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  •  go-up   go-down


7. Huang H, Bhat A, Woodnutt G, Lappe R: Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer; 2010 Aug;10(8):575-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiopoietins (ANGPTs) are ligands of the endothelial cell receptor TIE2 and have crucial roles in the tumour angiogenic switch.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651738.001).
  • [ISSN] 1474-1768
  • [Journal-full-title] Nature reviews. Cancer
  • [ISO-abbreviation] Nat. Rev. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiopoietins; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, TIE-2
  • [Number-of-references] 160
  •  go-up   go-down


8. Wang J, Milner R: Fibronectin promotes brain capillary endothelial cell survival and proliferation through alpha5beta1 and alphavbeta3 integrins via MAP kinase signalling. J Neurochem; 2006 Jan;96(1):148-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We showed previously that blood vessel maturation in the CNS is associated with a developmental switch in brain capillary endothelial cells (BCEC), from fibronectin signalling during angiogenesis to laminin signalling in the adult.
  • To investigate the functional significance of this switch, we have examined the response of BCEC to different extracellular matrix (ECM) proteins.
  • Taken together, these findings show that fibronectin exerts a strong angiogenic influence on endothelial cells (EC) in the CNS, and that this is mediated through the alpha5beta1 and alphavbeta3 integrins via MAP kinase signalling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269008.001).
  • [ISSN] 0022-3042
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fibronectins; 0 / Integrin alpha5beta1; 0 / Integrin alphaVbeta3; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


9. Siemerink MJ, Augustin AJ, Schlingemann RO: Mechanisms of ocular angiogenesis and its molecular mediators. Dev Ophthalmol; 2010;46:4-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complex interactions are involved between non-vascular and microvascular cells, such as endothelial cells and pericytes, via several angiogenic growth factors and inhibitors.
  • During the angiogenic process, endothelial cells shift from a homogeneous quiescent population into a population of heterogeneous phenotypes, each with a distinct cellular fate.
  • So far, three angiogenic specialized phenotypes have been identified:.
  • In most of these conditions, angiogenesis is part of a wound healing response culminating, via an angiofibrotic switch, in fibrosis and scar formation which leads to blindness.

  • MedlinePlus Health Information. consumer health - Eye Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20703029.001).
  • [ISSN] 1662-2790
  • [Journal-full-title] Developments in ophthalmology
  • [ISO-abbreviation] Dev Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Angiogenesis Inhibitors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


10. Gevertz JL, Torquato S: Modeling the effects of vasculature evolution on early brain tumor growth. J Theor Biol; 2006 Dec 21;243(4):517-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The properties of the vasculature and hence of each cell are determined by the relative concentrations of these key angiogenic factors.
  • The model exhibits an angiogenic switch consistent with experimental observations on the upregulation of angiogenesis.
  • Furthermore, we show that tumor expansion can occur in well-vascularized environments even when angiogenesis is inhibited, suggesting that anti-angiogenic therapies may not be sufficient to eliminate a population of actively dividing malignant cells.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938311.001).
  • [ISSN] 0022-5193
  • [Journal-full-title] Journal of theoretical biology
  • [ISO-abbreviation] J. Theor. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiopoietins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


11. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology; 2005;69 Suppl 3:4-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The production of VEGF and other growth factors by the tumor results in the 'angiogenic switch', where new vasculature is formed in and around the tumor, allowing it to grow exponentially.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16301830.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 45
  •  go-up   go-down


12. Rao VU, Shenoy AM, Karthikeyan B: Role of angiogenetic markers to predict neck node metastasis in head and neck cancers. J Cancer Res Ther; 2010 Apr-Jun;6(2):142-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The angiogenic switch may be one of the earliest events in conferring a metastatic potential to the tumor.
  • The present article reviews the utility value of various angiogenic parameters and markers that have been utilized to predict regional metastasis including micro vessel density, positive and negative regulators of angiogenesis, and genetic markers for angiogenesis.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20622359.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


13. Kim MS, Kim YK, Cho KH, Chung JH: Infrared exposure induces an angiogenic switch in human skin that is partially mediated by heat. Br J Dermatol; 2006 Dec;155(6):1131-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infrared exposure induces an angiogenic switch in human skin that is partially mediated by heat.
  • OBJECTIVES: To elucidate the molecular regulation of the angiogenic switch by acute near-IR radiation or by a single heat treatment in human skin in vivo.
  • CONCLUSIONS: Our results suggest that IR radiation plays an important role in skin angiogenesis via regulation of the balance between the angiogenic inducer VEGF and the angiogenic inhibitor TSP-2, and that IR-induced skin angiogenesis might be partially caused by the effects of heat in human skin in vivo.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107379.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Thrombospondins; 0 / Vascular Endothelial Growth Factor A; 0 / thrombospondin 2
  •  go-up   go-down


14. Rosenblatt MI, Azar DT: Anti-angiogenic therapy: Prospects for treatment of ocular tumors. Semin Ophthalmol; 2006 Jul-Sep;21(3):151-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-angiogenic therapy: Prospects for treatment of ocular tumors.
  • Angiogenesis research has identified a host of pro- and anti-angiogenic factors that regulate an "angiogenic switch," which when turned on, allows tumors to assume a more aggressive form.
  • Angiogensis inhibitors that target this switch are in clinical trials for a wide array of tumor types.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912013.001).
  • [ISSN] 0882-0538
  • [Journal-full-title] Seminars in ophthalmology
  • [ISO-abbreviation] Semin Ophthalmol
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY10101
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  • [Number-of-references] 51
  •  go-up   go-down


15. Glinskii OV, Abraha TW, Turk JR, Glinsky VV, Huxley VH: PDGF/VEGF system activation and angiogenesis following initial post ovariectomy meningeal microvessel loss. Cell Cycle; 2008 May 15;7(10):1385-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It appears that the latter serves as a molecular switch favoring angiogenic responses rather than further regression of destabilized microvessels.
  • Indeed, consistent with this idea, we have found a considerable angiogenic activity in meningeal microvascular networks that previously underwent regression.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] News Physiol Sci. 2002 Oct;17:197-201 [12270956.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7241-8 [16103075.001]
  • [Cites] Clin Exp Metastasis. 2003;20(5):451-8 [14524535.001]
  • [Cites] J Physiol. 2004 Jan 1;554(Pt 1):89-99 [14678494.001]
  • [Cites] Circ Res. 2004 May 14;94(9):1186-94 [15059936.001]
  • [Cites] EMBO J. 2006 May 17;25(10):2075-82 [16628216.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2768-78 [11387210.001]
  • [Cites] Genes Dev. 2003 Jun 1;17(11):1346-51 [12782653.001]
  • [Cites] Kobe J Med Sci. 2004 Jan;50(1-2):21-30 [15342968.001]
  • [Cites] Cell Cycle. 2006 Sep;5(18):2057-9 [16969103.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H1131-7 [17496211.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):4064-73 [10921887.001]
  • [Cites] J Biol Chem. 1995 Jun 2;270(22):13333-40 [7768934.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6020-4 [11507045.001]
  • [Cites] Kidney Int. 2005 Aug;68(2):695-703 [16014047.001]
  • [Cites] Dev Biol. 1995 Jun;169(2):699-712 [7781909.001]
  • [Cites] Circ Res. 1995 Sep;77(3):638-43 [7641334.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30336-43 [9804796.001]
  • (PMID = 18418080.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL078816-04W1; United States / NHLBI NIH HHS / HL / R01 HL078816; United States / NHLBI NIH HHS / HL / HL-52490; United States / NHLBI NIH HHS / HL / T32 HL007094; United States / NHLBI NIH HHS / HL / R37 HL042528; United States / NHLBI NIH HHS / HL / P01 HL052490; United States / NHLBI NIH HHS / HL / R37 HL042528-15; United States / NHLBI NIH HHS / HL / 5R01 HL078816-03; United States / NHLBI NIH HHS / HL / T32 HL007094-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Hypoxia-Inducible Factor 1; 0 / Platelet-Derived Growth Factor; 0 / Vascular Endothelial Growth Factor A; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 3.1.4.3 / Phospholipase C gamma
  • [Other-IDs] NLM/ NIHMS370834; NLM/ PMC3332329
  •  go-up   go-down


16. Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, Karczmar G, Salgia R: A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res; 2007 Apr 15;67(8):3529-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PHA665752 also inhibited angiogenesis by >85% in all the abovementioned cell lines and caused an angiogenic switch which resulted in a decreased production of vascular endothelial growth factor and an increase in the production of the angiogenesis inhibitor thrombospondin-1.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440059.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 100750-04; United States / NCI NIH HHS / CA / CA 125541-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one; 0 / Indoles; 0 / Sulfones; 0 / Thrombospondin 1; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


17. Nozawa H, Chiu C, Hanahan D: Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A; 2006 Aug 15;103(33):12493-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis.
  • In this article, we have identified two inflammatory cell types that are major sources of MMP-9 in the angiogenic stages of pancreatic islet carcinogenesis that unfold in RIP1-Tag2 transgenic mice.
  • MMP-9-expressing neutrophils were predominantly found inside angiogenic islet dysplasias and tumors, whereas MMP-9-expressing macrophages were localized along the periphery of such lesions.
  • Transient depletion of neutrophils significantly suppressed VEGF:VEGF-receptor association, a signature of MMP-9 activity, and markedly reduced the frequency of initial angiogenic switching in dysplasias.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1985 May 9-15;315(6015):115-22 [2986015.001]
  • [Cites] Immunogenetics. 1983;18(3):229-39 [6618532.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(15):5859-63 [2762301.001]
  • [Cites] J Immunol Methods. 1994 Sep 14;174(1-2):83-93 [8083541.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51630-46 [15355971.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):2018-25 [15753402.001]
  • [Cites] Cancer Cell. 2005 May;7(5):411-23 [15894262.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4037-51 [15806157.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] FASEB J. 2005 Dec;19(14):2005-7 [16223785.001]
  • [Cites] Int Immunol. 2006 Jan;18(1):1-9 [16352631.001]
  • [Cites] J Liposome Res. 2002 Feb-May;12(1-2):81-94 [12604042.001]
  • [Cites] Neurol Res. 2000 Jul;22(5):465-8 [10935217.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] Blood. 2001 Jan 15;97(2):339-45 [11154206.001]
  • [Cites] J Cell Physiol. 2001 Nov;189(2):197-206 [11598905.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] J Immunol. 2002 Jun 1;168(11):5798-804 [12023382.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):193-202 [12086877.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Int J Cancer. 2003 Jan 20;103(3):335-43 [12471616.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] J Exp Med. 2003 Apr 21;197(8):1017-28 [12695493.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8614-25 [14612405.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2221-32 [14633597.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Cancer Cell. 2004 May;5(5):443-53 [15144952.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2053-8 [15164120.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(11):1660-7 [15251154.001]
  • [Cites] Immunity. 2004 Aug;21(2):137-48 [15308095.001]
  • [Cites] Infect Immun. 2004 Sep;72(9):4956-65 [15321987.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):623-33 [15343380.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):409-21 [15488763.001]
  • [Cites] Nature. 1987 Jan 15-21;325(6101):223-8 [3543686.001]
  • (PMID = 16891410.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / GTPase-Activating Proteins; 0 / Gr-1 protein, mouse; 0 / Ralbp1 protein, mouse; 0 / Receptors, Chemokine; 0 / Vascular Endothelial Growth Factor A; 143011-72-7 / Granulocyte Colony-Stimulating Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC1531646
  •  go-up   go-down


18. Banerjee S, Mehta S, Haque I, Sengupta K, Dhar K, Kambhampati S, Van Veldhuizen PJ, Banerjee SK: VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis. Biochemistry; 2008 Mar 18;47(11):3345-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Collectively, these results establish, for the first time, a mechanistic link among VEGF-A 165, NRP-1, VEGFR1, and PI3K/Akt in the regulation of migration of human vascular smooth muscle cells that eventually could be involved in the angiogenic switch.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284215.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1P20 RR15563
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Blocking; 0 / Peptide Fragments; 0 / Protein Isoforms; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A (138-165); 144713-63-3 / Neuropilin-1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.11.1 / Oncogene Protein v-akt
  •  go-up   go-down


19. Naumov GN, Folkman J, Straume O, Akslen LA: Tumor-vascular interactions and tumor dormancy. APMIS; 2008 Jul-Aug;116(7-8):569-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor progression is dependent on a number of sequential steps, including initial tumor-vascular interactions and recruitment of blood vessels (i.e., the angiogenic switch), as well as tumor cells interacting with the surrounding microenvironment and its different components.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834403.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA45548
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor
  • [Number-of-references] 122
  •  go-up   go-down


20. Tacconelli A, Farina AR, Cappabianca L, Gulino A, Mackay AR: Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma. Future Oncol; 2005 Oct;1(5):689-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma.
  • TrkAIII exhibits neuroblastoma xenograft tumor-promoting activity associated with the induction of a more angiogenic and stress-resistant neuroblastoma phenotype and antagonises nerve growth factor/TrkAI antioncogenic signaling.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556046.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, trkA
  • [Number-of-references] 58
  •  go-up   go-down


21. Raica M, Mogoantă L, Cîmpean AM, Alexa A, Ioanovici S, Mărgăritescu C, Lazăr D, Izvernariu D: Immunohistochemical expression of vascular endothelial growth factor (VEGF) in intestinal type gastric carcinoma. Rom J Morphol Embryol; 2008;49(1):37-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was demonstrated the expression of VEGF in intestinal metaplasia and gastric dysplasia, which could signify an early angiogenic switch during tumorigenesis.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273500.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


22. Ribatti D: The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol; 2005 Feb;128(3):303-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is controlled by the net balance between molecules that have positive and negative regulatory activity and this concept had led to the notion of the 'angiogenic switch', depending on an increased production of one or more of the positive regulators of angiogenesis.
  • Numerous inducers of angiogenesis have been identified and this review offers a historical account of the relevant literature concerning the discovery of one of the best characterized angiogenic factors, namely vascular endothelial growth factor (VEGF)/vascular permeability factor.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667531.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Angiogenesis Inhibitors; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 63
  •  go-up   go-down


23. Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, Pruneri G, Shultz LD, Bertolini F: Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer; 2008 Nov 1;123(9):2222-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The leukemia-related angiogenic switch (measured as the number of circulating endothelial cells and progenitors) was faster in NSG compared to NS and NSB mice.


24. Mundel TM, Kalluri R: Type IV collagen-derived angiogenesis inhibitors. Microvasc Res; 2007 Sep-Nov;74(2-3):85-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The concept of anti-angiogenesis therapy was introduced by Judah Folkman in 1971 and since then, a plethora of pro- and anti-angiogenic factors have been identified.
  • In the recent years, it has become clear that angiogenesis, the formation of new capillaries from a pre-existing capillary network, is highly regulated by the action of pro- and anti-angiogenic factors.
  • In the healthy adult organism the "angiogenic-switch" is likely turned "Off", i. e. anti-angiogenic factors are likely counteracting the pro-angiogenic factors resulting in a non-angiogenic state.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2002 Dec;979:80-93 [12543719.001]
  • [Cites] Curr Opin Obstet Gynecol. 2003 Feb;15(1):45-9 [12544501.001]
  • [Cites] Ophthalmologe. 2003 Feb;100(2):104-10 [12589453.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2543-56 [12815141.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):589-601 [12842087.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2002;67:255-66 [12858548.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37632-6 [12876280.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 19;312(3):801-5 [14680836.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 28;318(2):354-60 [15120609.001]
  • [Cites] Ann Surg. 1972 Mar;175(3):409-16 [5077799.001]
  • [Cites] Eur J Biochem. 1981 Nov;120(2):203-11 [6274634.001]
  • [Cites] FEBS Lett. 1987 Dec 10;225(1-2):188-94 [3691802.001]
  • [Cites] J Cell Biol. 1988 Apr;106(4):1365-73 [3360855.001]
  • [Cites] J Biol Chem. 1988 Dec 15;263(35):19112-8 [3198614.001]
  • [Cites] J Biol Chem. 1988 Dec 25;263(36):19488-93 [3198637.001]
  • [Cites] J Biol Chem. 1989 Feb 5;264(4):2313-23 [2914908.001]
  • [Cites] Science. 1990 Jan 5;247(4938):77-9 [1688470.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(4):1606-10 [1689491.001]
  • [Cites] Am J Hum Genet. 1990 Jun;46(6):1024-33 [2339699.001]
  • [Cites] J Cell Biol. 1990 Oct;111(4):1583-91 [2211826.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1992;27(1-2):93-127 [1309319.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] Kidney Int. 1993 Jan;43(1):147-50 [7679456.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1757-65 [11337373.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2801-10 [16151532.001]
  • [Cites] Science. 2006 Aug 18;313(5789):968-71 [16917063.001]
  • [Cites] Sci STKE. 2006 Sep 26;2006(354):pe35 [17003465.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11331-40 [17145879.001]
  • [Cites] J Biol Chem. 2006 Dec 15;281(50):38117-21 [17082192.001]
  • [Cites] Nat Med. 2000 Jan;6(1):41-8 [10613822.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1209-15 [10625665.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):8051-61 [10713126.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2520-6 [10811134.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21340-8 [10766752.001]
  • [Cites] J Biol Chem. 2000 Aug 4;275(31):23745-50 [10837460.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15240-8 [11278365.001]
  • [Cites] Sci Am. 2001 Dec;285(6):38-45 [11759584.001]
  • [Cites] Science. 2002 Jan 4;295(5552):140-3 [11778052.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Apr;11(2):171-8 [11983091.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] J Biol Chem. 1994 May 6;269(18):13193-9 [8175748.001]
  • [Cites] J Biol Chem. 1994 Sep 16;269(37):23013-7 [8083201.001]
  • [Cites] J Biol Chem. 1994 Oct 21;269(42):26172-7 [7523402.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1157-64 [7528107.001]
  • [Cites] Annu Rev Biochem. 1995;64:403-34 [7574488.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Curr Opin Cell Biol. 1996 Oct;8(5):618-24 [8939648.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] J Clin Invest. 1997 May 15;99(10):2470-8 [9153291.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20395-401 [9252346.001]
  • [Cites] Transpl Immunol. 1997 Sep;5(3):179-83 [9402683.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2004 Dec;36(12):845-50 [15592653.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3967-79 [15899784.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4353-61 [15899827.001]
  • [Cites] Nat Rev Drug Discov. 2007 Apr;6(4):273-86 [17396134.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):292-8 [15979458.001]
  • (PMID = 17602710.001).
  • [ISSN] 0026-2862
  • [Journal-full-title] Microvascular research
  • [ISO-abbreviation] Microvasc. Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK61688; United States / NIDDK NIH HHS / DK / DK55001; United States / NIDDK NIH HHS / DK / R01 DK081576; United States / NIDDK NIH HHS / DK / R01 DK061688; United States / NIDDK NIH HHS / DK / R01 DK062987-04; United States / NIDDK NIH HHS / DK / R01 DK061688-03; United States / NIDDK NIH HHS / DK / R01 DK062987; United States / NIDDK NIH HHS / DK / R01 DK055001; United States / NIDDK NIH HHS / DK / R01 DK055001-07S1; United States / NIDDK NIH HHS / DK / DK62987; United States / NIAAA NIH HHS / AA / AA53194
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Collagen Type IV
  • [Number-of-references] 62
  • [Other-IDs] NLM/ NIHMS34602; NLM/ PMC3998721
  •  go-up   go-down


25. Kim MS, Oh YJ, Lee S, Kim JE, Kim KH, Chung JH: Ultraviolet radiation attenuates thrombospondin 1 expression via PI3K-Akt activation in human keratinocytes. Photochem Photobiol; 2006 May-Jun;82(3):645-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have demonstrated that UV radiation induces an angiogenic switch, by which it alters the balance between pro- and anti-angiogenic factors in the skin.
  • [MeSH-minor] Angiogenic Proteins / genetics. Angiogenic Proteins / radiation effects. Down-Regulation / genetics. Down-Regulation / radiation effects. Humans. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16478297.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / Thrombospondin 1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


26. Evensen L, Micklem DR, Link W, Lorens JB: A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery. Cytometry A; 2010 Jan;77(1):41-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery.
  • The successful progression to the clinic of angiogenesis inhibitors for cancer treatment has spurred interest in developing new classes of anti-angiogenic compounds.
  • Initially, EC are dependent on vSMC-derived VEGF and sensitive to clinical anti-angiogenic therapeutics.
  • A subsequent phenotypic VEGF-switch renders EC networks resistant to anti-VEGF therapeutics, demarcating a mature vascular phenotype.
  • Therefore, candidate anti-angiogenic compounds can be interrogated for their relative potency on immature and mature networks and classified as either vascular normalizing or vascular disrupting agents.
  • Here, we demonstrate that the EC-vSMC co-culture assay represents a robust high-content imaging high-throughput screening system for identification of novel anti-angiogenic agents.
  • High-throughput screening using the EC-vSMC co-culture assay establishes a new platform to screen for novel anti-angiogenic compounds for cancer therapy.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834964.001).
  • [ISSN] 1552-4930
  • [Journal-full-title] Cytometry. Part A : the journal of the International Society for Analytical Cytology
  • [ISO-abbreviation] Cytometry A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  •  go-up   go-down


27. Roth P, Hammer C, Piguet AC, Ledermann M, Dufour JF, Waelti E: Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2. J Drug Target; 2007 Nov;15(9):623-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These findings suggest that IL designed to bind specifically to VEGFR-2 can be used to deliver doxorubicin to the tumour endothelium and may impair the "angiogenic switch" of the tumours.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17968716.001).
  • [ISSN] 1061-186X
  • [Journal-full-title] Journal of drug targeting
  • [ISO-abbreviation] J Drug Target
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 80168379AG / Doxorubicin; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


28. Khan GN, Merajver SD: Modulation of angiogenesis for cancer prevention: strategies based on antioxidants and copper deficiency. Curr Pharm Des; 2007;13(35):3584-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The possibility of interfering very early in tumor progression by modulating the cancer angiogenic switch is appealing.
  • In this chapter, we review progress with in vitro and in vivo models that show that anti-angiogenic interventions may be amenable to long- term chemopreventive measures.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MOLYBDENUM .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18220795.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA77612
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anticarcinogenic Agents; 0 / Antioxidants; 0 / Chelating Agents; 0 / Flavonoids; 0 / NF-kappa B; 0 / Phenols; 0 / Polyphenols; 0 / Reactive Oxygen Species; 36-88-4 / Carotenoids; 789U1901C5 / Copper; 81AH48963U / Molybdenum; 91U3TGV99T / tetrathiomolybdate
  • [Number-of-references] 75
  •  go-up   go-down


29. Lee H, Baek S, Joe SJ, Pyo SN: Modulation of IFN-gamma production by TNF-alpha in macrophages from the tumor environment: significance as an angiogenic switch. Int Immunopharmacol; 2006 Jan;6(1):71-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of IFN-gamma production by TNF-alpha in macrophages from the tumor environment: significance as an angiogenic switch.
  • BACKGROUND: The role of macrophages in tumor angiogenesis has been known to influence in the production of angiogenic cytokines and growth factors including TNF-alpha.
  • Recently, macrophages were also found to produce INF-gamma, which were found to be involved in angiogenic inhibition.
  • Thus, the importance of macrophages in tumor angiogenesis might be the angiogenic switch.
  • The hypothesis tested here is that TNF-alpha can modulate the INF-gamma production in macrophages in tumor environment as part of the tumor angiogenic switch.
  • CONCLUSION: The overall data suggest that the macrophages in tumor environment might play an important role not only in angiogenic signal but also in anti-angiogenic signal by producing related cytokines.
  • Moreover, TNF-alpha might be a key cytokine functioning as a tumor angiogenic switch.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16332515.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Lipopolysaccharides; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


30. Siekmann AF, Lawson ND: Notch signalling and the regulation of angiogenesis. Cell Adh Migr; 2007 Apr-Jun;1(2):104-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During angiogenic sprouting, endothelial cells exhibit a diverse array of cellular behaviors.
  • In particular, this work has identified a conserved role for the Notch signalling pathway in limiting the cellular angiogenic response, in part by reducing the level of vascular endothelial growth factor receptors in endothelial cells.
  • In this overview, we discuss the emerging concepts elucidated by these studies and propose a model in which Notch acts reiteratively throughout the angiogenic process, likely by acting as a switch to determine a cell's response to Vegf.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1313-8 [10837024.001]
  • [Cites] Cardiovasc Res. 2001 Feb 16;49(3):568-81 [11166270.001]
  • [Cites] Mech Dev. 2001 Oct;108(1-2):161-4 [11578869.001]
  • [Cites] Development. 2001 Oct;128(19):3675-83 [11585794.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] J Cell Biol. 2003 Jun 23;161(6):1163-77 [12810700.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Blood. 2006 Feb 1;107(3):931-9 [16219802.001]
  • [Cites] Nature. 2006 Jun 8;441(7094):746-9 [16760977.001]
  • [Cites] Development. 2007 Mar;134(5):839-44 [17251261.001]
  • [Cites] Nature. 2007 Feb 15;445(7129):781-4 [17259972.001]
  • [Cites] Nature. 2007 Feb 15;445(7129):776-80 [17259973.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3219-24 [17296940.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3225-30 [17296941.001]
  • (PMID = 19329884.001).
  • [ISSN] 1933-6926
  • [Journal-full-title] Cell adhesion & migration
  • [ISO-abbreviation] Cell Adh Migr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Notch; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2633979
  •  go-up   go-down


31. Furness MS, Robinson TP, Ehlers T, Hubbard RB 4th, Arbiser JL, Goldsmith DJ, Bowen JP: Antiangiogenic agents: studies on fumagillin and curcumin analogs. Curr Pharm Des; 2005;11(3):357-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alteration of the delicate balance of angiogenic stimulating factors and angiogenic inhibitors results in the phenotypic change from quiescence to active endothelial proliferation.
  • To date, this angiogenic switch is not completely understood.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723631.001).
  • [ISSN] 1381-6128
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cyclohexanes; 0 / Fatty Acids, Unsaturated; 0 / Sesquiterpenes; 7OW73204U1 / fumagillin; IT942ZTH98 / Curcumin
  • [Number-of-references] 51
  •  go-up   go-down


32. Lucerna M, Pomyje J, Mechtcheriakova D, Kadl A, Gruber F, Bilban M, Sobanov Y, Schabbauer G, Breuss J, Wagner O, Bischoff M, Clauss M, Binder BR, Hofer E: Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res; 2006 Jul 01;66(13):6708-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transient induction of the transcription factor early growth response protein-1 (EGR-1) plays a pivotal role in the transcriptional response of endothelial cells to the angiogenic growth factors vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), which are produced by most tumors and are involved in the angiogenic switch.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 1992 Oct;67(4):519-28 [1279270.001]
  • [Cites] J Clin Invest. 2002 Mar;109(6):777-85 [11901186.001]
  • [Cites] Cancer Gene Ther. 2001 Nov;8(11):869-78 [11773977.001]
  • [Cites] Nat Med. 2000 Dec;6(12):1355-61 [11100120.001]
  • [Cites] Cell. 2004 Sep 17;118(6):781-94 [15369676.001]
  • [Cites] Nat Med. 2001 May;7(5):575-83 [11329059.001]
  • [Cites] Oncogene. 2001 Jun 21;20(28):3695-702 [11439332.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28706-14 [15105421.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8262-70 [15548693.001]
  • [Cites] Gene Ther. 1998 Aug;5(8):1105-13 [10326034.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;50:191-224 [7754034.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):859-68 [14668816.001]
  • [Cites] Hum Gene Ther. 2004 May;15(5):433-43 [15144574.001]
  • [Cites] Oncogene. 2003 Jan 16;22(2):291-7 [12527898.001]
  • [Cites] Mol Cell Biol. 1996 Jul;16(7):3545-53 [8668170.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3042-8 [12506026.001]
  • [Cites] Dev Growth Differ. 1997 Dec;39(6):729-40 [9493833.001]
  • [Cites] Genomics. 2002 Feb;79(2):266-70 [11829497.001]
  • [Cites] J Intern Med. 2004 May;255(5):538-61 [15078497.001]
  • [Cites] Cancer Cell Int. 2004 Jan 7;4(1):1 [14711380.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11433-40 [12427750.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1319-28 [15020672.001]
  • [Cites] Nat Med. 2003 Aug;9(8):1026-32 [12872165.001]
  • [Cites] Mol Cell. 2004 Jul 2;15(1):83-94 [15225550.001]
  • [Cites] Int J Cancer. 2004 Sep 1;111(3):348-57 [15221961.001]
  • [Cites] Nature. 2003 Apr 3;422(6931):527-31 [12673251.001]
  • [Cites] J Biol Chem. 1994 Oct 14;269(41):25646-54 [7929268.001]
  • [Cites] J Cell Sci. 1991 Aug;99 ( Pt 4):777-87 [1770005.001]
  • [Cites] Nat Med. 2003 Apr;9(4):407-15 [12652295.001]
  • [Cites] Am J Pathol. 1999 Mar;154(3):665-70 [10079243.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9349-54 [9689083.001]
  • [Cites] Nature. 2004 Feb 26;427(6977):787 [14985739.001]
  • [Cites] EMBO J. 2005 Jan 12;24(1):128-37 [15616591.001]
  • [Cites] Microvasc Res. 1994 Nov;48(3):349-63 [7537351.001]
  • (PMID = 16818645.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / S 9403
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2882226; NLM/ UKMS30448
  •  go-up   go-down


33. Pinto AV, Martins PR, Romagnoli GG, Campanelli AP, Terezan AP, Filho ER, Ferreira da Eira A, Kaneno R: Polysaccharide fraction of Agaricus brasiliensis avoids tumor-induced IL-10 production and changes the microenvironment of subcutaneous Ehrlich adenocarcinoma. Cell Immunol; 2009;256(1-2):27-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analysis of in situ expression of angiogenic growth factors showed a slight decrease of FGF-2 mRNA in Ehr-ATF animals (7th day) but not of VEGF-A or TGF-beta expression.
  • This fraction could not directly lyse either lymphocytes or tumor cells and we speculate that antitumor effect of ATF could be due to induction of a selective migration of immunocompetent cells from the spleen to the tumor site and to the switch of cytokine production.
  • [MeSH-minor] Angiogenic Proteins / genetics. Animals. Cytokines / biosynthesis. In Vitro Techniques. Interferon-gamma / biosynthesis. Lymphocyte Activation / drug effects. Lymphocytes, Tumor-Infiltrating / drug effects. Lymphocytes, Tumor-Infiltrating / pathology. Magnetic Resonance Spectroscopy. Male. Mice. Mice, Inbred BALB C. Molecular Structure. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19243740.001).
  • [ISSN] 1090-2163
  • [Journal-full-title] Cellular immunology
  • [ISO-abbreviation] Cell. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / Cytokines; 0 / Polysaccharides; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 130068-27-8 / Interleukin-10; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


34. Munaut C, Colige AC, Lambert CA: Alternative splicing: a promising target for pharmaceutical inhibition of pathological angiogenesis? Curr Pharm Des; 2010;16(35):3864-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this issue, we discuss some key examples showing how alternative splicing may induce a switch from anti-angiogenic to pro-angiogenic functions and reciprocally.
  • The emergence of strategies enabling to regulate alternative splicing opens new routes for anti-angiogenic therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21158727.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


35. Yue F, Zhang GP, Jin HM: Effects of basic fibroblast growth factor on the expressions of angiogenic gene profile and cyclooxygenase-2 in brain microvascular endothelial cells. Sheng Li Xue Bao; 2006 Apr 25;58(2):124-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of basic fibroblast growth factor on the expressions of angiogenic gene profile and cyclooxygenase-2 in brain microvascular endothelial cells.
  • The effects of bFGF (10 ng/ml) on mRNA and protein expressions of cyclooxygenase-2 (COX-2), an angiogenesis bystander molecule, were further investigated. cDNA microarray was employed to study the effects of bFGF on the expressions of angiogenic genes in a high throughput pattern.
  • The results showed that, 2 h after bFGF treatment, pro-angiogenic genes (Adamts1, MMP-9, Ang-1, PDGF B, G-CSF, FGF16, IGF-1, etc.) were significantly upregulated, whereas anti-angiogenic genes (TIMP-2, TSP-3, etc.) were significantly downregulated.
  • The bystander molecule in angiogenic pathway COX-2 mRNA and protein expressions were significantly upregulated after bFGF treatment.
  • It is suggested that triggering angiogensis switch through upregulating pro-angiogenic gene and downregulating anti-angiogenic gene expression is one of the major mechanisms of bFGF-induced angiogenesis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628358.001).
  • [ISSN] 0371-0874
  • [Journal-full-title] Sheng li xue bao : [Acta physiologica Sinica]
  • [ISO-abbreviation] Sheng Li Xue Bao
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 103107-01-3 / Fibroblast Growth Factor 2; EC 1.14.99.- / Ptgs2 protein, mouse; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


36. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ: Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia; 2005 Nov;48(11):2422-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.
  • VEGF is alternatively spliced to form the angiogenic (VEGF(xxx)) and potentially anti-angiogenic (VEGF(xxx)b) family of isoforms.
  • CONCLUSIONS/INTERPRETATION: Since VEGF(xxx)b inhibits VEGF(xxx)-induced angiogenesis in a one-to-one stoichiometric manner, these results show that in the eye of diabetic patients VEGF splicing was switched from an anti-angiogenic to a pro-angiogenic environment.

  • MedlinePlus Health Information. consumer health - Diabetic Eye Problems.
  • MedlinePlus Health Information. consumer health - Eye Care.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7822-35 [15520188.001]
  • [Cites] Diabetes. 2002 May;51(5):1635-9 [11978667.001]
  • [Cites] Mol Endocrinol. 2001 Dec;15(12):2197-210 [11731620.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Mar;40(3):752-9 [10067980.001]
  • [Cites] Vascul Pharmacol. 2002 Nov;39(4-5):225-37 [12747962.001]
  • [Cites] Ophthalmology. 2003 May;110(5):979-86 [12750101.001]
  • [Cites] Arch Ophthalmol. 1994 Nov;112(11):1476-82 [7980139.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2805-16 [15625332.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 7;92 (23 ):10457-61 [7479819.001]
  • [Cites] Diabetes Metab Res Rev. 2004 Mar-Apr;20(2):91-113 [15037985.001]
  • [Cites] Lab Invest. 1995 Jun;72 (6):638-45 [7540233.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4123-31 [12124351.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Apr;286(4):F767-73 [14644752.001]
  • [Cites] Am J Ophthalmol. 1994 Oct 15;118(4):445-50 [7943121.001]
  • [Cites] Retina. 2002 Apr;22(2):143-52 [11927845.001]
  • (PMID = 16193288.001).
  • [ISSN] 0012-186X
  • [Journal-full-title] Diabetologia
  • [ISO-abbreviation] Diabetologia
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / VEGFB protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor B
  •  go-up   go-down


37. Coulon C, Georgiadou M, Roncal C, De Bock K, Langenberg T, Carmeliet P: From vessel sprouting to normalization: role of the prolyl hydroxylase domain protein/hypoxia-inducible factor oxygen-sensing machinery. Arterioscler Thromb Vasc Biol; 2010 Dec;30(12):2331-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the forefront of a vessel sprout, "tip cells" guide the sprouting vessel toward an angiogenic stimulus.
  • For this purpose, endothelial cells switch to the "phalanx" cell fate, which is characterized by quiescent and nonproliferating cells aligned in a tight cobblestonelike layer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20966400.001).
  • [ISSN] 1524-4636
  • [Journal-full-title] Arteriosclerosis, thrombosis, and vascular biology
  • [ISO-abbreviation] Arterioscler. Thromb. Vasc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / endothelial PAS domain-containing protein 1; EC 1.14.11.2 / Procollagen-Proline Dioxygenase; S88TT14065 / Oxygen
  •  go-up   go-down


38. Tassi E, Wellstein A: The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma. Semin Oncol; 2006 Dec;33(6 Suppl 11):S50-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3098-103 [10340381.001]
  • [Cites] Oncogene. 1999 Apr 29;18(17):2747-54 [10348349.001]
  • [Cites] J Clin Invest. 1999 Aug;104(3):263-9 [10430607.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1071-5 [10470088.001]
  • [Cites] Mutat Res. 1999 Aug;406(2-4):71-7 [10479724.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] Curr Opin Genet Dev. 1999 Oct;9(5):595-603 [10508699.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):107-37 [15863029.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Lab Invest. 2005 Jun;85(6):747-55 [15806140.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Jul;55(1):67-81 [15890525.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R105-13 [16352855.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):1137-44 [16257968.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1191-8 [16424058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12 [9539785.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):361-81 [10666364.001]
  • [Cites] Oncogene. 2000 Jan 27;19(4):546-55 [10698524.001]
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] Trends Cell Biol. 2000 Apr;10(4):147-54 [10740269.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1363-80 [10751361.001]
  • [Cites] Clin Exp Immunol. 2000 Apr;120(1):59-65 [10759764.001]
  • [Cites] J Clin Gastroenterol. 2000 Apr;30(3):230-3 [10777178.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1821-5 [10854204.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Endocr Relat Cancer. 2000 Sep;7(3):165-97 [11021964.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10263-71 [11148217.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] J Biol Chem. 2001 Oct 26;276(43):40247-53 [11509569.001]
  • [Cites] Oncology (Williston Park). 2001 Oct;15(10):1241-9, 1254; discussion 1254-64 [11702956.001]
  • [Cites] Gut. 2002 Jul;51(1):56-9 [12077092.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):301-13 [12105858.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Cytokine. 2002 Nov 24;20(4):184-90 [12543084.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1696-705 [12670924.001]
  • [Cites] Pancreas. 2003 May;26(4):344-9 [12717266.001]
  • [Cites] Ann Surg Oncol. 2003 Aug;10(7):722-33 [12900362.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8085-9 [14678957.001]
  • [Cites] Pancreas. 2004 Jan;28(1):25-30 [14707726.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Expert Opin Investig Drugs. 2004 Jun;13(6):631-41 [15174949.001]
  • [Cites] Mol Cancer. 2003 Jan 7;2:8 [12556241.001]
  • [Cites] Trends Genet. 2004 Nov;20(11):563-9 [15475116.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Ann Surg. 1972 Mar;175(3):409-16 [5077799.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):293-7 [3587348.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):298-303 [2438556.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Science. 1989 Apr 14;244(4901):217-21 [2649981.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16778-85 [1885605.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5289-96 [7693336.001]
  • [Cites] Science. 1993 Dec 10;262(5140):1731-4 [8259518.001]
  • [Cites] Science. 1993 Dec 10;262(5140):1734-7 [8259519.001]
  • [Cites] Genomics. 1994 Feb;19(3):525-31 [8188295.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2043-50 [7931472.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5953-8 [7954428.001]
  • [Cites] J Biol Chem. 1994 Nov 11;269(45):28243-8 [7525570.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3046-50 [7708772.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 4;215(1):309-15 [7575607.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1727-32 [8929264.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):843-8 [8922199.001]
  • [Cites] J Pathol. 1996 Dec;180(4):364-70 [9014855.001]
  • [Cites] Nat Med. 1997 Feb;3(2):177-82 [9018236.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):390-5 [9139874.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2671-81 [9178765.001]
  • [Cites] Biochim Biophys Acta. 1997 Jun 7;1332(3):F127-47 [9196022.001]
  • [Cites] Curr Biol. 1997 Jul 1;7(7):R443-6 [9210368.001]
  • [Cites] Oncogene. 1997 Sep 18;15(12):1417-24 [9333017.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1137-40 [9334727.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):798-807 [9516401.001]
  • [Cites] Pancreas. 1998 Aug;17(2):169-75 [9700949.001]
  • [Cites] Eur J Cancer. 1998 Mar;34(4):518-21 [9713302.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Kidney Int Suppl. 1998 Sep;67:S3-6 [9736244.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):765-70 [9743297.001]
  • [Cites] Oncogene. 1998 Sep 17;17(11 Reviews):1395-413 [9779987.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):139-44 [9874785.001]
  • [Cites] Curr Top Microbiol Immunol. 1999;237:97-132 [9893348.001]
  • [Cites] J Clin Invest. 1999 Jan;103(2):159-65 [9916127.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(4):383-91 [9931387.001]
  • (PMID = 17178288.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL068686; United States / NCI NIH HHS / CA / R01 CA071508; United States / NCI NIH HHS / CA / R01 CA108440; United States / NCI NIH HHS / CA / R01 CA71508
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Intercellular Signaling Peptides and Proteins; 139946-12-6 / FGFBP1 protein, human
  • [Number-of-references] 98
  • [Other-IDs] NLM/ NIHMS15609; NLM/ PMC1781498
  •  go-up   go-down


39. Galiè M, Konstantinidou G, Peroni D, Scambi I, Marchini C, Lisi V, Krampera M, Magnani P, Merigo F, Montani M, Boschi F, Marzola P, Orrù R, Farace P, Sbarbati A, Amici A: Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene; 2008 Apr 17;27(18):2542-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also found that MTCs and MSCs have the same molecular signature for stemness-related genes, and that when co-implanted with cancer cells in syngeneic animals MSCs determine early tumor appearance, probably by favoring the angiogenic switch.
  • [MeSH-major] Angiogenic Proteins / biosynthesis. Gene Expression Regulation, Neoplastic. Mammary Neoplasms, Animal / metabolism. Mesenchymal Stem Cell Transplantation / adverse effects. Mesenchymal Stromal Cells / metabolism. Neovascularization, Pathologic / metabolism

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998939.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenic Proteins
  •  go-up   go-down


40. Ardi VC, Van den Steen PE, Opdenakker G, Schweighofer B, Deryugina EI, Quigley JP: Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J Biol Chem; 2009 Sep 18;284(38):25854-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By quantifying the levels of host angiogenic factors, we demonstrated that basic fibroblast growth factor (FGF-2) was a major cytokine becoming bioavailable in the onplant tissue undergoing a neutrophil proMMP-9-mediated angiogenic switch.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Mol Med. 2002 Jul-Sep;6(3):439-46 [12417062.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):153-66 [12784994.001]
  • [Cites] Eur J Biochem. 2003 Sep;270(18):3739-49 [12950257.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4007-16 [14610089.001]
  • [Cites] Circ Res. 2004 Feb 6;94(2):262-8 [14670843.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1675-86 [14996727.001]
  • [Cites] J Cell Sci. 2004 Apr 1;117(Pt 9):1847-57 [15075244.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29589-97 [15123665.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2002 Dec;37(6):375-536 [12540195.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):617-29 [15286728.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):409-21 [15488763.001]
  • [Cites] Biochem Biophys Res Commun. 1982 May 14;106(1):170-4 [6285913.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6162-70 [2169335.001]
  • [Cites] J Biol Chem. 1992 Oct 25;267(30):21712-9 [1400481.001]
  • [Cites] J Cell Sci. 1993 Apr;104 ( Pt 4):991-9 [8314909.001]
  • [Cites] Hybridoma. 1993 Aug;12(4):349-63 [8244415.001]
  • [Cites] Dev Biol. 1995 Jul;170(1):39-49 [7601314.001]
  • [Cites] Biochem J. 1995 Jul 1;309 ( Pt 1):299-306 [7619071.001]
  • [Cites] J Biol Chem. 1995 Aug 4;270(31):18506-11 [7629179.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):26-45 [9034785.001]
  • [Cites] J Submicrosc Cytol Pathol. 1998 Jan;30(1):127-36 [9530860.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10672-81 [9553130.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1659-73 [9647657.001]
  • [Cites] J Biol Chem. 1999 May 7;274(19):13066-76 [10224058.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:497-9 [10415753.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3200-8 [15833851.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Biochim Biophys Acta. 2005 May 25;1755(1):37-69 [15907591.001]
  • [Cites] Lab Invest. 2005 Jun;85(6):747-55 [15806140.001]
  • [Cites] J Cell Biol. 2005 May 23;169(4):681-91 [15911882.001]
  • [Cites] J Exp Med. 2005 Sep 19;202(6):739-50 [16157686.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):728-34 [16524717.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):9-34 [16680569.001]
  • [Cites] J Biol Chem. 2006 Jul 7;281(27):18626-37 [16672230.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493-8 [16891410.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3310-9 [17409440.001]
  • [Cites] Cancer Sci. 2007 Apr;98(4):541-8 [17359289.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20262-7 [18077379.001]
  • [Cites] J Biol Chem. 2002 Dec 27;277(52):50326-32 [12384502.001]
  • [Cites] Biochemistry. 2008 Feb 26;47(8):2689-99 [18237197.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):193-205 [18328424.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):206-20 [18328425.001]
  • [Cites] Curr Opin Hematol. 2008 May;15(3):215-20 [18391788.001]
  • [Cites] Neoplasia. 2008 Apr;10(4):329-40 [18392134.001]
  • [Cites] Blood. 2008 Jul 1;112(1):169-78 [18326820.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):592-603 [18650835.001]
  • [Cites] Methods Enzymol. 2008;444:21-41 [19007659.001]
  • [Cites] J Cell Sci. 1999 Dec;112 ( Pt 23):4213-21 [10564640.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2673-81 [11023497.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] Lab Invest. 2001 Jan;81(1):61-75 [11204275.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2323-32 [11290594.001]
  • [Cites] J Leukoc Biol. 2001 Jun;69(6):851-9 [11404367.001]
  • [Cites] FASEB J. 2002 Mar;16(3):379-89 [11874987.001]
  • [Cites] Proteomics. 2001 Nov;1(11):1359-63 [11922595.001]
  • [Cites] Cell. 2002 May 31;109(5):625-37 [12062105.001]
  • [Cites] J Mol Biol. 2002 Jul 26;320(5):1065-79 [12126625.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42 [12165638.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1429-37 [12368215.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):589-601 [12842087.001]
  • (PMID = 19608737.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA105412; United States / NHLBI NIH HHS / HL / T32 HL007195; United States / NCI NIH HHS / CA / CA105412; United States / NCI NIH HHS / CA / CA55852; United States / NHLBI NIH HHS / HL / 5T32 HL07195-31; United States / NCI NIH HHS / CA / R01 CA055852; United States / NCI NIH HHS / CA / R01 CA129484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Precursors; 0 / Tissue Inhibitor of Metalloproteinase-1; 103107-01-3 / Fibroblast Growth Factor 2; EC 2.7.10.1 / FGFR2 protein, human; EC 2.7.10.1 / Fgfr2 protein, mouse; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2; EC 3.4.24.- / pro-matrix metalloproteinase 9; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2757987
  •  go-up   go-down


41. Shojaei F, Singh M, Thompson JD, Ferrara N: Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A; 2008 Feb 19;105(7):2640-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, the role of neutrophils in RIP-Tag angiogenic switching, as assessed by systemic ablation using anti-Gr1 antibodies at different stages of tumor progression, has been recently described.
  • Here, we show that early treatment of RIP-Tag mice with anti-Bv8 antibodies resulted in a significant reduction in the number of angiogenic islets relative to control antibody-treated mice, implicating Bv8 in the angiogenic switch during neoplasia.
  • Histological analysis showed a significant reduction in vascular surface areas in hyperplastic and angiogenic lesions in pancreatic islets from anti-Bv8-treated mice.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1999 Nov 19;461(3):183-8 [10567694.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):825-31 [18064003.001]
  • [Cites] Mol Pharmacol. 2001 Apr;59(4):692-8 [11259612.001]
  • [Cites] Nature. 2001 Aug 30;412(6850):877-84 [11528470.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):8724-9 [11751915.001]
  • [Cites] Nature. 2002 May 23;417(6887):405-10 [12024206.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19276-80 [11886876.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 26;293(1):396-402 [12054613.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):193-202 [12086877.001]
  • [Cites] Nat Med. 2002 Sep;8(9):913-7 [12205443.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2685-90 [12604792.001]
  • [Cites] EMBO Rep. 2003 May;4(5):469-73 [12728244.001]
  • [Cites] Endocrinology. 2003 Jun;144(6):2606-16 [12746324.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):409-21 [15488763.001]
  • [Cites] Hoppe Seylers Z Physiol Chem. 1980 Dec;361(12):1787-94 [7461607.001]
  • [Cites] Nature. 1996 Apr 4;380(6573):439-42 [8602242.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Mol Biol. 1998;283(1):205-19 [9761684.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] Eur J Pharmacol. 1999 Jun 18;374(2):189-96 [10422759.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16813-8 [15548611.001]
  • [Cites] Science. 2005 Jun 24;308(5730):1923-7 [15976302.001]
  • [Cites] J Leukoc Biol. 2005 Aug;78(2):426-34 [15908459.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):211-26 [16169466.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):951-61 [16278208.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4140-5 [16537498.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493-8 [16891410.001]
  • [Cites] PLoS Genet. 2006 Oct 20;2(10):e175 [17054399.001]
  • [Cites] Annu Rev Med. 2007;58:491-504 [17052163.001]
  • [Cites] Nat Biotechnol. 2007 Aug;25(8):911-20 [17664940.001]
  • [Cites] Cancer J. 2007 Nov-Dec;13(6):345-8 [18032969.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • (PMID = 18268320.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Gastrointestinal Hormones; 0 / Insulin; 0 / Neuropeptides; 0 / Prok2 protein, mouse
  • [Other-IDs] NLM/ PMC2268189
  •  go-up   go-down


42. Yoder MC, Ingram DA: Endothelial progenitor cell: ongoing controversy for defining these cells and their role in neoangiogenesis in the murine system. Curr Opin Hematol; 2009 Jul;16(4):269-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: Highlighted articles identify a critical role for these cells in promoting the angiogenic switch for growth of metastatic tumors or find no role at all for these circulating cells as engrafting cells in vascular endothelium or as promoters of tumor growth.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417649.001).
  • [ISSN] 1531-7048
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


43. Schipani E: Hypoxia and HIF-1 alpha in chondrogenesis. Semin Cell Dev Biol; 2005 Aug-Oct;16(4-5):539-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The chondrocytic growth plate is a unique mesenchymal tissue, as it is avascular but it requires blood vessel invasion, i.e. the angiogenic switch, in order to be replaced by bone.
  • The findings overall highlight the usefulness of studying fetal growth plate development as a model to address issues such as adaptation of normal tissues to hypoxia, survival of hypoxic cells, and regulation of the angiogenic switch.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16144691.001).
  • [ISSN] 1084-9521
  • [Journal-full-title] Seminars in cell & developmental biology
  • [ISO-abbreviation] Semin. Cell Dev. Biol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR 048191
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  • [Number-of-references] 54
  •  go-up   go-down


44. Taveau JC, Dubois M, Le Bihan O, Trépout S, Almagro S, Hewat E, Durmort C, Heyraud S, Gulino-Debrac D, Lambert O: Structure of artificial and natural VE-cadherin-based adherens junctions. Biochem Soc Trans; 2008 Apr;36(Pt 2):189-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This novel link is labile and promotes the endothelial cell switch from a quiescent to an angiogenic state.

  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Struct Biol. 2004 Oct;148(1):131-5 [15363793.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29786-93 [9792693.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):873-81 [2831236.001]
  • [Cites] Annu Rev Biochem. 1990;59:237-52 [2197976.001]
  • [Cites] Development. 1999 May;126(10):2093-102 [10207135.001]
  • [Cites] Cell. 1999 Jul 23;98(2):147-57 [10428027.001]
  • [Cites] J Mol Biol. 2005 Mar 11;346(5):1193-6 [15713473.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4337-44 [15701713.001]
  • [Cites] Development. 2005 Sep;132(18):4165-78 [16123312.001]
  • [Cites] Cell. 2005 Dec 2;123(5):889-901 [16325582.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1255-68 [16564015.001]
  • [Cites] J Mol Biol. 2007 Jan 19;365(3):744-51 [17095015.001]
  • [Cites] Annu Rev Neurosci. 2007;30:451-74 [17600523.001]
  • [Cites] J Mol Biol. 2007 Oct 19;373(2):401-11 [17850815.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3581-8 [11069895.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12790-801 [11821414.001]
  • [Cites] Science. 2002 May 17;296(5571):1308-13 [11964443.001]
  • [Cites] Blood. 2002 Aug 1;100(3):905-11 [12130501.001]
  • [Cites] Science. 2003 Oct 3;302(5642):109-13 [14526082.001]
  • [Cites] J Cell Biol. 1992 Sep;118(6):1511-22 [1522121.001]
  • [Cites] Science. 1995 Jan 20;267(5196):386-9 [7824937.001]
  • [Cites] Nature. 1995 Mar 23;374(6520):327-37 [7885471.001]
  • [Cites] Cell. 1996 Feb 9;84(3):345-57 [8608588.001]
  • [Cites] Curr Biol. 1997 May 1;7(5):308-15 [9133345.001]
  • [Cites] J Cell Biol. 1978 Nov;79(2 Pt 1):427-43 [569157.001]
  • (PMID = 18363560.001).
  • [ISSN] 0300-5127
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Cadherins; 0 / Membranes, Artificial
  • [Number-of-references] 27
  • [Other-IDs] NLM/ HALMS433365; NLM/ PMC2798065
  •  go-up   go-down


45. Teodoro JG, Evans SK, Green MR: Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med (Berl); 2007 Nov;85(11):1175-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The combination of these effects allows p53 to efficiently shut down the angiogenic potential of cancer cells.
  • Thus, the loss of functional p53 during tumorigenesis likely represents an essential step in the switch to an angiogenic phenotype that is displayed by aggressive tumors.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1997 Aug 11;138(3):707-17 [9245797.001]
  • [Cites] Mol Cell Biol. 1994 Sep;14 (9):6264-77 [8065358.001]
  • [Cites] Trends Mol Med. 2003 Feb;9(2):73-8 [12615041.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):4975-83 [15107830.001]
  • [Cites] Science. 2006 Aug 18;313(5789):968-71 [16917063.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4855-78 [8069852.001]
  • [Cites] J Histochem Cytochem. 2001 Sep;49(9):1143-53 [11511683.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7717-22 [2253215.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21340-8 [10766752.001]
  • [Cites] Cell. 1998 Jun 26;93(7):1159-70 [9657149.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Cancer Gene Ther. 2002 Jan;9(1):28-36 [11916242.001]
  • [Cites] J Vasc Res. 2000 May-Jun;37(3):209-18 [10859480.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1765(2):178-88 [16406676.001]
  • [Cites] Br J Cancer. 1987 Dec;56(6):814-9 [2829956.001]
  • [Cites] Nat Genet. 1994 Oct;8(2):171-6 [7531056.001]
  • [Cites] Cell Death Differ. 2003 Apr;10(4):404-8 [12719716.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2520-6 [10811134.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1582-4 [7521539.001]
  • [Cites] Annu Rev Biochem. 1995;64:403-34 [7574488.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6952-7 [11559575.001]
  • [Cites] Science. 2001 Apr 20;292(5516):464-8 [11292862.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):2-4 [1988084.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5866-9 [9865747.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9009-13 [8090761.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):617-20 [11956638.001]
  • [Cites] Cancer Gene Ther. 2001 Oct;8(10):771-82 [11687900.001]
  • [Cites] Nat Med. 2000 Jan;6(1):41-8 [10613822.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1994;59:483-9 [7587102.001]
  • [Cites] Cell. 2006 Jan 13;124(1):207-19 [16413492.001]
  • [Cites] Int J Cancer. 1997 Oct 21;74(5):502-7 [9355971.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7011-26 [12370823.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):490-8 [10667605.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(4):1297-310 [11158315.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):88-91 [8538748.001]
  • [Cites] Oncogene. 1997 Oct;15(18):2145-50 [9393972.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1209-15 [10625665.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6503-15 [11641774.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):594-604 [12154352.001]
  • [Cites] J Biol Chem. 2007 Jun 1;282(22):16187-201 [17420250.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16266-71 [17056717.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2934-9 [15710885.001]
  • [Cites] J Biol Chem. 1996 Nov 29;271(48):30741-7 [8940053.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5096-104 [15958553.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Nucleic Acids Res. 2000 Jun 1;28(11):2268-75 [10871348.001]
  • [Cites] Acta Histochem. 2004;106(2):111-21 [15147632.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2301-6 [11280802.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5614-9 [11114742.001]
  • [Cites] EMBO J. 1998 Jun 1;17(11):3005-15 [9606183.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Genes Dev. 1998 Jan 15;12(2):149-62 [9436976.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):10911-5 [10196169.001]
  • [Cites] Cell. 2004 Nov 24;119(5):591-602 [15550242.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5684-91 [8971176.001]
  • [Cites] Science. 2002 Feb 22;295(5559):1526-8 [11859195.001]
  • [Cites] J Cell Biol. 1993 Jul;122(2):497-511 [7686555.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):219-31 [12676581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6624-8 [1697685.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6504-11 [7527299.001]
  • [Cites] N Engl J Med. 1993 Apr 29;328(17):1237-43 [8464435.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7907-12 [14633720.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Oncogene. 1998 Aug 20;17(7):819-24 [9779998.001]
  • [Cites] Cancer. 1963 Apr;16:453-67 [13958548.001]
  • [Cites] Clin Exp Metastasis. 2003;20(1):59-68 [12650608.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Feb 24;255(3):735-9 [10049780.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1990-3 [12702593.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Oncogene. 2005 May 19;24(22):3632-42 [15782143.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):454-66 [7509851.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):462-75 [15928710.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(13):5757-66 [15199132.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):159-72 [15923088.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6330-8 [9343394.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7830-9 [11691800.001]
  • [Cites] Int J Cancer. 1993 Nov 11;55(5):739-44 [8244569.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):34-8 [9495355.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2128-31 [10786673.001]
  • [Cites] Nat Med. 2003 Jun;9(6):677-84 [12778166.001]
  • [Cites] Nature. 2004 Feb 26;427(6977):787 [14985739.001]
  • [Cites] Science. 2001 Jul 13;293(5528):293-7 [11452123.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 23;289(1):264-8 [11708810.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):531-8 [2408737.001]
  • [Cites] Cancer Gene Ther. 2004 Nov;11(11):757-66 [15359289.001]
  • [Cites] Cell Growth Differ. 1994 Dec;5(12):1373-80 [7696186.001]
  • [Cites] Nature. 1998 Jul 30;394(6692):485-90 [9697772.001]
  • [Cites] Eur J Hum Genet. 2001 Nov;9(11):811-4 [11781696.001]
  • [Cites] Prostate Cancer Prostatic Dis. 1997 Sep;1(1):39-44 [12496932.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):8051-61 [10713126.001]
  • [Cites] Genes Dev. 2000 Jan 1;14(1):34-44 [10640274.001]
  • (PMID = 17589818.001).
  • [ISSN] 0946-2716
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 98
  •  go-up   go-down


46. Jouanneau E: Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery; 2008 Jan;62(1):31-50; discussion 50-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypoxia and genetic anomalies within a glioma trigger the angiogenic switch, thus upregulating angiogenic factors and downregulating antiangiogenic factors.
  • This article summarizes the mechanisms of the angiogenic switch based on tumor grade and subtype, reviews completed and ongoing clinical trials, and details the present and the future of surrogate markers for angiogenesis in gliomas.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300890.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Angiogenesis Inhibitors; 0 / Biomarkers
  • [Number-of-references] 216
  •  go-up   go-down


47. Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, Seano G, Serini G, Bussolino F, Giraudo E: Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest; 2009 Nov;119(11):3356-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pharmacologic inhibition of endogenous Sema3A during the angiogenic switch, the point when pretumoral lesions initiate an angiogenic phase that persists throughout tumor growth, enhanced angiogenesis and accelerated tumor progression.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):584-93 [16445911.001]
  • [Cites] Diabetes. 2006 Apr;55(4):875-84 [16567506.001]
  • [Cites] Trends Biochem Sci. 2006 Apr;31(4):231-9 [16530415.001]
  • [Cites] Blood. 2006 May 15;107(10):3892-901 [16424390.001]
  • [Cites] Endothelium. 2006 Mar-Apr;13(2):81-91 [16728327.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1661-7 [16684957.001]
  • [Cites] Nat Med. 2006 Dec;12(12):1380-9 [17099709.001]
  • [Cites] J Clin Invest. 2000 Feb;105(3):261-70 [10675351.001]
  • [Cites] Mech Dev. 2000 Oct;97(1-2):35-45 [11025205.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Mech Dev. 2001 Nov;109(1):115-9 [11677062.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):193-202 [12086877.001]
  • [Cites] Nat Med. 2002 Sep;8(9):918-21 [12205444.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11854-9 [12192090.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):933-41 [12370271.001]
  • [Cites] Int J Cancer. 2003 Apr 20;104(4):496-503 [12584749.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] Nature. 2003 Jul 24;424(6947):391-7 [12879061.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):42985-91 [12933805.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):383-91 [14667505.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):393-403 [14667506.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1008-15 [14871832.001]
  • [Cites] Genes Dev. 2004 Feb 15;18(4):435-47 [14977921.001]
  • [Cites] Mol Cell Neurosci. 2004 Apr;25(4):722-31 [15080899.001]
  • [Cites] Biochem Soc Trans. 2004 Jun;32(Pt3):421-5 [15157151.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):623-33 [15343380.001]
  • [Cites] Nature. 1985 May 9-15;315(6015):115-22 [2986015.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9051-5 [7692444.001]
  • [Cites] J Biol Chem. 1995 Oct 27;270(43):25570-7 [7592728.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2930-5 [8610145.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1899-917 [8952526.001]
  • [Cites] Clin Ther. 2006 Nov;28(11):1779-802 [17212999.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):53-67 [17222790.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1451-60 [17308083.001]
  • [Cites] J Biol Chem. 2007 Sep 7;282(36):26294-305 [17569671.001]
  • [Cites] Cell. 2007 Nov 2;131(3):463-75 [17981115.001]
  • [Cites] Front Biosci. 2008;13:2653-9 [17981740.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):421-31 [17768598.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2674-80 [18180379.001]
  • [Cites] Nat Med. 2008 Mar;14(3):255-7 [18278052.001]
  • [Cites] Circ Res. 2008 Mar 14;102(5):562-70 [18202311.001]
  • [Cites] Trends Biochem Sci. 2008 Apr;33(4):161-70 [18374575.001]
  • [Cites] J Exp Med. 2008 May 12;205(5):1155-71 [18458115.001]
  • [Cites] Nature. 2008 May 15;453(7193):410-4 [18418378.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):632-45 [18580951.001]
  • [Cites] PLoS One. 2008;3(9):e3287 [18818766.001]
  • [Cites] Nat Rev Cancer. 2008 Dec;8(12):942-56 [19029957.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1294-300 [9102216.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] J Neurochem. 1999 Sep;73(3):961-71 [10461885.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1260-71 [15520858.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):193-211 [15972964.001]
  • [Cites] Nature. 2005 Jul 14;436(7048):193-200 [16015319.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6167-77 [16024618.001]
  • [Cites] Nat Cell Biol. 2005 Sep;7(9):870-9 [16113679.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8317-23 [16166308.001]
  • [Cites] Circ Res. 2005 Sep 16;97(6):512-23 [16166562.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):1-11 [16356825.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):198-211 [16397233.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2006 Mar;290(3):H1220-5 [16258027.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):255-61 [16478744.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):651-8 [16325811.001]
  • (PMID = 19809158.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP04127; Italy / Telethon / / GGP09175; United States / NIDDK NIH HHS / DK / DK59936; United States / NIAAA NIH HHS / AA / P60 AA11999
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antigens, CD29; 0 / Semaphorin-3A
  •  go-up   go-down


48. Rojas A, Silva R, Figueroa H, Morales MA: Oxidative stress in tumor microenvironment--Its role in angiogenesis. Zhongguo Fei Ai Za Zhi; 2008 Jun 20;11(3):297-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor angiogenesis process is believed to be dependent on an "angiogenic switch" formed by a cascade of biologic events as a consequence of the "cross-talk" between tumor cells and several components of local microenvironment including endothelial cells, macrophages, mast cells and stromal components.
  • Oxidative stress represents an important stimulus that widely contributes to this angiogenic switch, which is particularly relevant in lungs, where oxidative stress is originated from different sources including the incomplete reduction of oxygen during respiration, exposure to hypoxia/reoxygenation, stimulated resident or chemoattracted immune cells to lung tissues, as well as by a variety of chemicals compounds.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731924.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] China
  •  go-up   go-down


49. Pietras K, Hanahan D: A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol; 2005 Feb 10;23(5):939-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
  • PURPOSE: A transgenic mouse model has revealed parameters of the angiogenic switch during multistep tumorigenesis of pancreatic islets, and demonstrated efficacy of antiangiogenic therapies.
  • A "chemo-switch" protocol, involving sequential MTD and then metronomic chemotherapy, overlaid with multitargeted inhibition of PDGFR and VEGFR, gave complete responses and unprecedented survival advantage in this model.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15557593.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Benzamides; 0 / Indoles; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Pyrroles; 0 / sunitinib; 8A1O1M485B / Imatinib Mesylate; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


50. Prahst C, Héroult M, Lanahan AA, Uziel N, Kessler O, Shraga-Heled N, Simons M, Neufeld G, Augustin HG: Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. J Biol Chem; 2008 Sep 12;283(37):25110-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular endothelial growth factor (VEGF) acts as a hierarchically high switch of the angiogenic cascade by interacting with its high affinity VEGF receptors and with neuropilin co-receptors.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2178-89 [10786682.001]
  • [Cites] PLoS One. 2007;2(11):e1161 [18000534.001]
  • [Cites] Development. 2001 Sep;128(17):3359-70 [11546752.001]
  • [Cites] Mech Dev. 2001 Nov;109(1):115-9 [11677062.001]
  • [Cites] Matrix Biol. 2002 Mar;21(2):207-14 [11852236.001]
  • [Cites] J Cell Biochem. 2002;85(2):357-68 [11948691.001]
  • [Cites] FASEB J. 2004 May;18(7):929-31 [15001553.001]
  • [Cites] FEBS Lett. 2004 Aug 13;572(1-3):123-8 [15304335.001]
  • [Cites] Dev Biol. 1995 Jul;170(1):207-22 [7601310.001]
  • [Cites] Development. 1995 Dec;121(12):4309-18 [8575331.001]
  • [Cites] J Neurobiol. 1996 Jan;29(1):1-17 [8748368.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] Neuron. 1997 Nov;19(5):995-1005 [9390514.001]
  • [Cites] Cell. 1998 Mar 20;92(6):735-45 [9529250.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12340-5 [9770488.001]
  • [Cites] Curr Opin Neurobiol. 1998 Oct;8(5):587-92 [9811625.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1619-27 [10102632.001]
  • [Cites] J Neurosci. 1999 Aug 1;19(15):6519-27 [10414980.001]
  • [Cites] Development. 1999 Nov;126(21):4895-902 [10518505.001]
  • [Cites] Circ Res. 2005 Jun 24;96(12):1257-65 [15920019.001]
  • [Cites] Nat Med. 2006 Feb;12(2):235-9 [16462802.001]
  • [Cites] Dev Cell. 2006 Jun;10(6):783-95 [16740480.001]
  • [Cites] FASEB J. 2006 Jul;20(9):1513-5 [16754745.001]
  • [Cites] Traffic. 2006 Sep;7(9):1270-82 [17004325.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10264-8 [17079444.001]
  • [Cites] FASEB J. 2007 Mar;21(3):915-26 [17185751.001]
  • [Cites] J Biol Chem. 2007 Aug 17;282(33):24049-56 [17575273.001]
  • [Cites] Mol Biol Cell. 2001 Mar;12(3):615-27 [11251075.001]
  • (PMID = 18628209.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL 084619
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / GIPC1 protein, human; 0 / Gipc protein, mouse; 0 / Neuropeptides; 0 / Vascular Endothelial Growth Factor A; 144713-63-3 / Neuropilin-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC2533068
  •  go-up   go-down


51. Zaslavsky A, Baek KH, Lynch RC, Short S, Grillo J, Folkman J, Italiano JE Jr, Ryeom S: Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood; 2010 Jun 3;115(22):4605-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sequential events leading to tumor progression include a switch to the angiogenic phenotype, dependent on a shift in the balance between positive and negative angiogenic regulators produced by tumor and stromal cells.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Drug Discov. 2007 Apr;6(4):273-86 [17396134.001]
  • [Cites] J Clin Invest. 2006 Dec;116(12):3277-91 [17143334.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):264-73 [17637752.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1201-7 [17914028.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1227-33 [17962514.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2835-42 [19036702.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):9024-8 [17494758.001]
  • [Cites] J Biol Chem. 2000 Jan 21;275(3):1521-4 [10636838.001]
  • [Cites] Thromb Haemost. 2001 Jul;86(1):23-33 [11487011.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1949-56 [11696456.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Cell Mol Med. 2002 Jan-Mar;6(1):1-12 [12003665.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):473-83 [12498716.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):219-31 [12676581.001]
  • [Cites] J Thromb Haemost. 2003 Apr;1(4):853-4 [12871428.001]
  • [Cites] J Thromb Haemost. 2003 Jun;1(6):1174-82 [12871316.001]
  • [Cites] Blood. 2004 Jan 1;103(1):152-4 [14504091.001]
  • [Cites] Nature. 2004 Feb 26;427(6977):787 [14985739.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1038-45 [15094119.001]
  • [Cites] Proc Natl Acad Sci U S A. 1968 Sep;61(1):46-52 [5246932.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Biol Chem. 1972 May 10;247(9):2723-31 [4260214.001]
  • [Cites] Surgery. 1973 Aug;74(2):235-40 [4577805.001]
  • [Cites] J Biol Chem. 1978 Dec 10;253(23):8609-16 [101549.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):3880-3 [6378376.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):3884-7 [6744304.001]
  • [Cites] Haemostasis. 1988;18(1):29-36 [3047021.001]
  • [Cites] Biochemistry. 1992 Feb 4;31(4):1173-80 [1734965.001]
  • [Cites] Int J Hematol. 1993 Aug;58(1-2):105-12 [7693024.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2853-8 [8194026.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1582-4 [7521539.001]
  • [Cites] Cell. 1995 Jun 2;81(5):695-704 [7774011.001]
  • [Cites] Exp Hematol. 1995 Aug;23(9):996-1001 [7635185.001]
  • [Cites] J Biol Chem. 1996 Nov 29;271(48):30741-7 [8940053.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):632-8 [9477093.001]
  • [Cites] J Clin Invest. 1998 Mar 1;101(5):982-92 [9486968.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6343-8 [9600967.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4446-52 [9834252.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1775-7 [9848370.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):496-507 [15563312.001]
  • [Cites] Br J Pharmacol. 2004 Dec;143(7):819-26 [15492016.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):216-20 [15615851.001]
  • [Cites] J Cell Biol. 2005 Feb 14;168(4):643-53 [15716381.001]
  • [Cites] Cancer Invest. 2005;23(3):193-200 [15945504.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10280-8 [16288016.001]
  • [Cites] Br J Haematol. 2006 May;133(3):251-8 [16643426.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1765(2):178-88 [16406676.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:389-97 [16869776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16266-71 [17056717.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):355-62 [17097558.001]
  • [CommentIn] Blood. 2010 Jun 3;115(22):4326-7 [20522719.001]
  • (PMID = 20086246.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA045548; United States / NHLBI NIH HHS / HL / R01 HL068130; United States / NCI NIH HHS / CA / P01 CA045548-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA Primers; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Thrombospondin 1
  • [Other-IDs] NLM/ PMC2881490
  •  go-up   go-down


52. Almog N: Molecular mechanisms underlying tumor dormancy. Cancer Lett; 2010 Aug 28;294(2):139-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although cancer can arise through multiple pathways, it is assumed that essentially most tumors begin as microscopic, non-angiogenic neoplasms which cannot expand in size until vasculature is established.
  • Additionally, analogies and distinctions between the concepts of "tumor dormancy" and that of the "cellular dormancy" of tumor cells, as well as between the "exit from tumor dormancy" and the "onset of the angiogenic switch" are discussed.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20363069.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Ireland
  • [Number-of-references] 69
  •  go-up   go-down


53. Miyazawa M, Dong Z, Zhang Z, Neiva KG, Cordeiro MM, Oliveira DT, Nör JE: Effect of PTK/ZK on the angiogenic switch in head and neck tumors. J Dent Res; 2008 Dec;87(12):1166-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of PTK/ZK on the angiogenic switch in head and neck tumors.
  • Transformation of small avascular masses of tumor cells into rapidly progressive cancers is triggered by the angiogenic switch, a process that involves vascular endothelial growth factor (VEGF) signaling.
  • We have shown that VEGF enhances the survival and angiogenic potential of endothelial cells by activating the Bcl-2-CXCL8 signaling axis.
  • Analysis of these data demonstrates that PTK/ZK blocks downstream targets of VEGF signaling in endothelial cells, and suggests that PTK/ZK may inhibit the angiogenic switch in head and neck tumors.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EXS. 2005;(94):209-31 [15617481.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1369-79 [10389921.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):558-65 [15705616.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5063-9 [15958549.001]
  • [Cites] Oncology. 2005;69 Suppl 3:4-10 [16301830.001]
  • [Cites] Laryngoscope. 2005 Dec;115(12):2249-55 [16369175.001]
  • [Cites] Head Neck. 2006 May;28(5):389-99 [16388530.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1378-86 [16729025.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):751-78 [16954429.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1779-87 [16931911.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):942-53 [17103252.001]
  • [Cites] Recent Results Cancer Res. 2007;174:219-24 [17302199.001]
  • [Cites] Oncologist. 2007 Apr;12(4):443-50 [17470687.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9685-93 [17942898.001]
  • [Cites] Bull Math Biol. 2008 Jan;70(1):89-117 [17701379.001]
  • [Cites] Crit Rev Oral Biol Med. 1999;10(2):153-64 [10759419.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2178-89 [10786682.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4819-24 [10987292.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2183-8 [11280784.001]
  • [Cites] Lab Invest. 2001 Apr;81(4):453-63 [11304564.001]
  • [Cites] Cancer Biother Radiopharm. 2001 Oct;16(5):359-70 [11776753.001]
  • [Cites] Oral Oncol. 2003 Apr;39(3):207-12 [12618192.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6020-9 [14676128.001]
  • [Cites] Nature. 2004 Feb 26;427(6977):787 [14985739.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):368-78 [7856749.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Biol Chem. 1998 May 22;273(21):13313-6 [9582377.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):375-84 [10027396.001]
  • [Cites] Chembiochem. 2005 Mar;6(3):550-7 [15742376.001]
  • (PMID = 19029087.001).
  • [ISSN] 1544-0591
  • [Journal-full-title] Journal of dental research
  • [ISO-abbreviation] J. Dent. Res.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / R01-DE15948; United States / NIDCR NIH HHS / DE / R01 DE014601-01; United States / NIDCR NIH HHS / DE / R01 DE014601; United States / NIDCR NIH HHS / DE / R01 DE016586-01; United States / NIDCR NIH HHS / DE / R01-DE14601; United States / NIDCR NIH HHS / DE / R01 DE016586; United States / NIDCR NIH HHS / DE / R01 DE015948-01; United States / NIDCR NIH HHS / DE / R01-DE16586; United States / NIDCR NIH HHS / DE / R01 DE015948
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Interleukin-8; 0 / Phthalazines; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyridines; 5DX9U76296 / vatalanib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Other-IDs] NLM/ NIHMS96082; NLM/ PMC2654254
  •  go-up   go-down


54. Zhang N, Zhong R, Perez-Pinera P, Herradon G, Ezquerra L, Wang ZY, Deuel TF: Identification of the angiogenesis signaling domain in pleiotrophin defines a mechanism of the angiogenic switch. Biochem Biophys Res Commun; 2006 May 5;343(2):653-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the angiogenesis signaling domain in pleiotrophin defines a mechanism of the angiogenic switch.
  • The appearance of new blood vessels in malignant tumors is known as the "angiogenic switch."
  • The angiogenic switch triggers a stage of rapid tumor growth supported by extensive tumor angiogenesis and a more aggressive tumor phenotype and its onset is a poor prognostic indicator for host survival.
  • Identification of the factors that stimulate the angiogenic switch thus is of high importance.
  • Pleiotrophin (PTN the protein, Ptn the gene) is an angiogenic factor and the Ptn gene has been found to be constitutively expressed in many human tumors of different cell types.
  • These studies use a nude mouse model to test if Ptn constitutively expressed in premalignant cells is sufficient to trigger an angiogenic switch in vivo.
  • SW-13 Ptn cell subcutaneous tumor implants grew very rapidly and had a striking increase in the density of new blood vessels compared to the SW-13 cell tumor implants, suggesting that constitutive PTN signaling in the premalignant SW-13 cell implants in the nude mouse recapitulates fully the angiogenic switch.
  • It was found also that ectopic expression of the C-terminal domain of PTN in SW-13 cell implants was equally effective in initiating an angiogenic switch as the full-length PTN whereas implants of SW-13 cells in nude mice that express the N-terminal domain of PTN grew rapidly but failed to develop tumor angiogenesis.
  • The data suggest the possibility that mutations that activate Ptn in premalignant cells are sufficient to stimulate an angiogenic switch in vivo and, since these mutations are frequently found in human malignancies, that constitutive PTN signaling may be an important contributor to progression of human tumors.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554021.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / 2 T32 DK007022-26; United States / NCI NIH HHS / CA / CA 66029; United States / NCI NIH HHS / CA / CA 84400; United States / NIDDK NIH HHS / DK / DK 53557; United States / PHS HHS / / NHLBI 31102
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Cytokines; 134034-50-7 / pleiotrophin
  •  go-up   go-down


55. Maier JA, Nasulewicz-Goldeman A, Simonacci M, Boninsegna A, Mazur A, Wolf FI: Insights into the mechanisms involved in magnesium-dependent inhibition of primary tumor growth. Nutr Cancer; 2007;59(2):192-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inhibition of LLC tumor growth in Mg-deficient mice is due to a direct effect of low Mg on LLC cell proliferation and to an impairment of the angiogenic switch.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18001214.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.14.13.39 / Nitric Oxide Synthase; I38ZP9992A / Magnesium
  •  go-up   go-down


56. Chen SH, Babichev Y, Rodrigues N, Voskas D, Ling L, Nguyen VP, Dumont DJ: Gene expression analysis of Tek/Tie2 signaling. Physiol Genomics; 2005 Jul 14;22(2):257-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using semiquantitative PCR, the differential expression of eight genes was confirmed that included Elk3, an important angiogenic switch gene which was upregulated in the absence of Tie2 signaling.
  • The results of this study provide valuable insight into the potential association between Tie2 signaling and other known angiogenic pathways as well as genes that might have novel functions in vascular remodeling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899944.001).
  • [ISSN] 1531-2267
  • [Journal-full-title] Physiological genomics
  • [ISO-abbreviation] Physiol. Genomics
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL-63224-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


57. Hemberger M: IFPA award in placentology lecture - characteristics and significance of trophoblast giant cells. Placenta; 2008 Mar;29 Suppl A:S4-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Giant cells are highly polyploid as a result of a switch from a mitotic to an endoreduplicative cell cycle.
  • Their angiogenic and vasodilatory properties, combined with the ability to remodel arterial walls, enable them to redirect maternal blood flow towards the implantation site.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18083226.001).
  • [ISSN] 0143-4004
  • [Journal-full-title] Placenta
  • [ISO-abbreviation] Placenta
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BBS/E/B/0000M100; United Kingdom / Medical Research Council / / G120/824; United Kingdom / Medical Research Council / /
  • [Publication-type] Lectures; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


58. Giatromanolaki A, Sivridis E, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, Koukourakis MI: Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas. J Surg Oncol; 2006 Sep 1;94(3):242-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To investigate the significance of the hypoxia inducible factors HIF-1alpha and HIF-2alpha in gallbladder adenocarcinomas and their relation to angiogenesis and to the expression of VEGF, an angiogenic factor transcriptionally regulated by HIFalphas.
  • In addition, the vascular density (VD) and the expression of the angiogenic factors VEGF and thymidine phosphorylase (TP) were examined.
  • Although HIFs did not relate significantly with prognosis, patients with HIF-1/2 expression who failed to switch-on VEGF or intratumoral angiogenesis had a favorable outcome.

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16900513.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factor A; 0 / endothelial PAS domain-containing protein 1
  •  go-up   go-down


59. Schaffner F, Versteeg HH, Schillert A, Yokota N, Petersen LC, Mueller BM, Ruf W: Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood; 2010 Dec 23;116(26):6106-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Simultaneous deletion of PAR2 in TF(ΔCT) mice did not further delay tumor appearance, consistent with overlapping roles of TF and PAR2 in promoting the angiogenic switch in early stages of breast cancer.
  • In advanced carcinomas, tumor-associated macrophages were reduced in TF(ΔCT) and TF(ΔCT)/PAR2(-/-) mice, and increased tumor vessel diameters of TF(ΔCT) mice were partially reversed by PAR2-deficiency, indicating that the TF cytoplasmic domain has additional roles that are interdependent with PAR2 signaling in regulating host angiogenic responses.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Guide to Pharmacology. gene/protein/disease-specific - PAR2 - data and references .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8205-9 [7667269.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1372-8 [9525979.001]
  • [Cites] Nat Med. 1998 Aug;4(8):909-14 [9701242.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8663-8 [10411932.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55419-24 [15489220.001]
  • [Cites] Thromb Res. 2005;116(1):75-85 [15850611.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19808-14 [15769747.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):307-14 [16397244.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):425-35 [16476770.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):744-50 [16439712.001]
  • [Cites] Semin Thromb Hemost. 2006 Apr;32 Suppl 1:61-8 [16673267.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jun 16;344(4):1263-70 [16650817.001]
  • [Cites] Biochemistry. 2006 Aug 8;45(31):9374-85 [16878972.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):355-62 [17097558.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10643-6 [17108099.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1456-62 [17363687.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5251-9 [17332247.001]
  • [Cites] Blood. 2007 Jul 1;110(1):133-41 [17371949.001]
  • [Cites] J Biol Chem. 2007 Jul 13;282(28):20634-46 [17500066.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jul;293(1):C346-57 [17442737.001]
  • [Cites] J Thromb Haemost. 2007 Aug;5(8):1588-97 [17470200.001]
  • [Cites] Blood. 2008 Jan 1;111(1):190-9 [17901245.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3413-20 [10552951.001]
  • [Cites] J Cell Biol. 2000 Mar 20;148(6):1267-81 [10725339.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7742-7 [11438726.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12485-90 [11606713.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2997-3000 [12782609.001]
  • [Cites] Chest. 2003 Sep;124(3 Suppl):58S-68S [12970125.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):109-17 [14695325.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):1990-9 [14966279.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3029-37 [15070680.001]
  • [Cites] Nat Med. 2004 May;10(5):502-9 [15098027.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23038-44 [15039423.001]
  • [Cites] Mol Biol Cell. 2004 Oct;15(10):4416-25 [15254262.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7219-27 [18757438.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1975-81 [18772494.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):208-16 [19118048.001]
  • [Cites] Pathophysiol Haemost Thromb. 2008;36(3-4):122-30 [19176985.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):1999-2004 [19661489.001]
  • [Cites] J Biol Chem. 2009 Dec 4;284(49):34444-57 [19815543.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22399-404 [20018779.001]
  • [Cites] Int J Cancer. 2010 May 15;126(10):2330-40 [19795460.001]
  • [Cites] Cell. 2010 Apr 2;141(1):39-51 [20371344.001]
  • [Cites] Methods. 2008 Feb;44(2):190-5 [18241800.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):2113-26 [14578209.001]
  • (PMID = 20861457.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL060742; United States / NHLBI NIH HHS / HL / HL-60742
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, PAR-2; 9035-58-9 / Thromboplastin
  • [Other-IDs] NLM/ PMC3031395
  •  go-up   go-down


60. Ria R, Reale A, Castrovilli A, Mangialardi G, Dammacco F, Ribatti D, Vacca A: Angiogenesis and progression in human melanoma. Dermatol Res Pract; 2010;2010:185687
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secretion of various angiogenic cytokines, i.e.
  • VEGF-A, FGF-2, PGF-1 and -2, IL-8, and TGF-1 by melanoma cells promote the angiogenic switch and has been correlated to transition from the radial to the vertical growth phase, and to the metastatic phase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1970 Nov;172(5):902-8 [5477666.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):455-61 [7686442.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4547-52 [8044805.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;213 ( Pt 1):65-80 [8814995.001]
  • [Cites] Invest New Drugs. 1996;14(2):193-202 [8913840.001]
  • [Cites] Surg Clin North Am. 1996 Dec;76(6):1223-55 [8977548.001]
  • [Cites] J Cutan Pathol. 1997 Apr;24(4):212-8 [9138111.001]
  • [Cites] Biochem Cell Biol. 1996;74(6):853-62 [9164653.001]
  • [Cites] Biochim Biophys Acta. 1997 May 27;1356(3):271-80 [9194570.001]
  • [Cites] Br J Cancer. 1997;76(7):930-4 [9328154.001]
  • [Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S19-26 [9578413.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2150-6 [9626215.001]
  • [Cites] Pathobiology. 1999;67(1):12-8 [9873223.001]
  • [Cites] Blood. 1999 May 1;93(9):3064-73 [10216103.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):733-43 [10360651.001]
  • [Cites] J Pathol. 1999 Sep;189(1):66-71 [10451490.001]
  • [Cites] J Pathol. 2000 Jul;191(3):245-56 [10878545.001]
  • [Cites] Neoplasia. 1999 Oct;1(4):293-302 [10935483.001]
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):337-44 [10951266.001]
  • [Cites] Recenti Prog Med. 2000 Nov;91(11):581-7 [11125952.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):584-92 [11208854.001]
  • [Cites] In Vivo. 2001 Mar-Apr;15(2):175-80 [11317524.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Invest New Drugs. 2002 Nov;20(4):431-7 [12448662.001]
  • [Cites] Eur J Cell Biol. 2002 Nov;81(11):599-607 [12494997.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):666-74 [12628847.001]
  • [Cites] Exp Dermatol. 2003 Apr;12(2):109-25 [12702139.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1648-55 [12738717.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):177-203 [12784996.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 4;1654(1):79-94 [14984769.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4048-54 [15217937.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1759-63 [15274352.001]
  • [Cites] Chest. 2004 Sep;126(3):926-34 [15364775.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8924-31 [15604254.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):81-4 [15944771.001]
  • [Cites] Cytokine. 2005 Aug 7;31(3):241-9 [15975819.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):195-222 [15986132.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5158-66 [16033831.001]
  • [Cites] J Dermatol Sci. 2006 Jan;41(1):11-9 [16216466.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(2):165-74 [16736151.001]
  • [Cites] Pigment Cell Res. 2006 Oct;19(5):395-405 [16965268.001]
  • [Cites] Leukemia. 2007 Jan;21(1):44-52 [16990761.001]
  • [Cites] Cancer Sci. 2006 Dec;97(12):1327-34 [16999819.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5471-80 [17000682.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2367-76 [17534686.001]
  • [Cites] Cancer. 2009 Jan 1;115(1):119-27 [19090009.001]
  • [Cites] Can J Ophthalmol. 2009 Feb;44(1):106-7 [19169330.001]
  • [Cites] Curr Pharm Des. 2009;15(4):389-410 [19199966.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:1571-88 [19273147.001]
  • [Cites] J Immunother. 2009 Jan;32(1):79-85 [19307996.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3495-502 [19447871.001]
  • [Cites] Chemotherapy. 2009;55(4):221-7 [19451711.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5287-97 [19738110.001]
  • [Cites] Med Hypotheses. 2010 Feb;74(2):360-1 [19744799.001]
  • [Cites] Anticancer Drugs. 2007 Nov;18(10):1221-6 [17893524.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1114-23 [17914081.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2269-75 [17932881.001]
  • [Cites] Br J Cancer. 1989 Jan;59(1):89-91 [2667611.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1270-8 [2963689.001]
  • [Cites] Am J Pathol. 1988 Nov;133(2):419-23 [3189515.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6):555-65 [18083379.001]
  • [Cites] Acta Oncol. 2008;47(8):1526-30 [18607876.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2139-45 [18792064.001]
  • [Cites] Microvasc Res. 2009 Mar;77(2):78-86 [18805433.001]
  • (PMID = 20631829.001).
  • [ISSN] 1687-6113
  • [Journal-full-title] Dermatology research and practice
  • [ISO-abbreviation] Dermatol Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2901609
  •  go-up   go-down


61. Vacca A, Scavelli C, Serini G, Di Pietro G, Cirulli T, Merchionne F, Ribatti D, Bussolino F, Guidolin D, Piaggio G, Bacigalupo A, Dammacco F: Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. Blood; 2006 Sep 01;108(5):1661-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show that the VEGF165-driven angiogenic potential of multiple myeloma (MM) ECs is significantly higher than that of monoclonal gammopathy of undetermined significance (MGUS) ECs (MGECs) and human umbilical vein (HUV) ECs.
  • Moreover, by counteracting VEGF165 activity as efficiently as an anti-VEGFR-2 antibody, exogenous SEMA3A restrains the over-angiogenic potential of MMECs.
  • Our data indicate that loss of endothelial SEMA3A in favor of VEGF165 could be responsible for the angiogenic switch from MGUS to MM.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16684957.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP04127
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / SEMA3A protein, human; 0 / Semaphorin-3A; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


62. Parsons-Wingerter P, Chandrasekharan UM, McKay TL, Radhakrishnan K, DiCorleto PE, Albarran B, Farr AG: A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity. Microvasc Res; 2006 Nov;72(3):91-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity.
  • Although vascular endothelial growth factor-165 (VEGF(165)) regulates numerous angiogenic cellular activities, its complex effects on vascular morphology are not highly quantified.
  • The VEGF-dependent phenotypic switch from normal vessels displaying increased vessel density to abnormal, dilated vessels typical of tumor vasculature and other pathologies resulted from an approximate threefold increase in VEGF concentration (1.25 to 5 microg/CAM) and correlated positively with increased eNOS activity.
  • In summary, VEGF(165) induced a phenotypic switch from increased vessel density associated with low VEGF concentration, to increased vessel diameter and increased eNOS activity at high VEGF concentration.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872639.001).
  • [ISSN] 0026-2862
  • [Journal-full-title] Microvascular research
  • [ISO-abbreviation] Microvasc. Res.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM-40711
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  •  go-up   go-down


63. Diaz-Gonzalez JA, Russell J, Rouzaut A, Gil-Bazo I, Montuenga L: Targeting hypoxia and angiogenesis through HIF-1alpha inhibition. Cancer Biol Ther; 2005 Oct;4(10):1055-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIF-1alpha plays a major role in the response of tumors to hypoxia, and it is mainly responsible for the "angiogenic switch".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16294030.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1
  • [Number-of-references] 105
  •  go-up   go-down


64. North S, Moenner M, Bikfalvi A: Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett; 2005 Jan 31;218(1):1-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors.
  • Angiogenesis in tumors is controlled by the so-called 'angiogenic switch' which allows the passage from low invasive and poorly vascularized tumors to highly invasive and angiogenic tumors.
  • A number of cellular stress factors such as hypoxia, nutrient deprivation or inducers of reactive oxygen species (ROS) are important stimuli of angiogenic signalling.
  • In addition, HIF-independent mechanisms have been described which involved number of other molecules and transcription factors such as nuclear factor-(kappa)B (NF-(kappa)B) and p53. p53 is an important intracellular mediator of the stress response and is now also recognized as a modifier of the angiogenic response. p53 may interact with the HIF system but may also have direct effects on angiogenesis regulators or interfere with translation mechanisms of angiogenesis factors.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15639335.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Micronutrients; 0 / Reactive Oxygen Species; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 125
  •  go-up   go-down


65. Islam A, Banerjee S, Kambhampati S, Baranda J, Banerjee S, Weston AP, Saxena NK, Banerjee SK: Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor. Front Biosci; 2006;11:2336-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor.
  • Activation of "Angiogenic switch" or formation of new blood vessels is one of the upshots of these abuses.
  • Multiple factors are associated with the activation of angiogenic switch.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720317.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 87680; United States / NCRR NIH HHS / RR / P20 RR015563
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 123
  •  go-up   go-down


66. Heckman-Stoddard BM, Vargo-Gogola T, McHenry PR, Jiang V, Herrick MP, Hilsenbeck SG, Settleman J, Rosen JM: Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression. Breast Cancer Res; 2009;11(4):R61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To examine gene expression of potential mediators of the angiogenic switch, an angiogenesis PCR array was utilized and results were confirmed using immunohistochemistry.
  • Angiogenesis was decreased in the p190B heterozygous tumors, and expression of a potent angiogenic inhibitor, thrombospondin-1, was elevated in p190B+/-Neu mammary glands.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Jun 15;19(26):3013-20 [10871853.001]
  • [Cites] Oncogene. 2009 Jul 16;28(28):2545-55 [19465939.001]
  • [Cites] Neoplasia. 2000 Sep-Oct;2(5):418-25 [11191108.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12485-90 [11606713.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Dec;127(12):733-8 [11768613.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6967-72 [12011455.001]
  • [Cites] Dev Cell. 2002 May;2(5):553-65 [12015964.001]
  • [Cites] Genes Dev. 2002 Jul 1;16(13):1587-609 [12101119.001]
  • [Cites] Biochim Biophys Acta. 2003 Mar 17;1603(2):47-82 [12618308.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):219-31 [12676581.001]
  • [Cites] Cell. 2003 Apr 18;113(2):147-58 [12705864.001]
  • [Cites] Mol Endocrinol. 2003 Jun;17(6):1054-65 [12637587.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Oncogene. 2004 Sep 9;23(41):6980-5 [15286714.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82 [1359541.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6504-11 [7527299.001]
  • [Cites] J Biol Chem. 1995 Dec 29;270(52):30919-26 [8537347.001]
  • [Cites] J Pathol. 1998 Feb;184(2):119-22 [9602700.001]
  • [Cites] EMBO J. 1999 Apr 15;18(8):2149-64 [10205169.001]
  • [Cites] Int J Cancer. 1999 May 31;81(5):682-7 [10328216.001]
  • [Cites] Cell Signal. 1999 Aug;11(8):545-54 [10433515.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2511-9 [10499627.001]
  • [Cites] Curr Opin Cell Biol. 2006 Apr;18(2):199-205 [16487696.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2931-6 [16331248.001]
  • [Cites] Mol Endocrinol. 2006 Jun;20(6):1391-405 [16469769.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):291-8 [16900393.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1779-87 [16931911.001]
  • [Cites] Development. 2007 Mar;134(6):1231-42 [17287253.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):389-97 [17446858.001]
  • [Cites] Dev Biol. 2007 Sep 1;309(1):137-49 [17662267.001]
  • [Cites] Front Biosci. 2008;13:759-76 [17981586.001]
  • [Cites] FEBS Lett. 2008 Jun 18;582(14):2093-101 [18460342.001]
  • [Cites] J Cell Sci. 2008 Jun 15;121(Pt 12):2054-61 [18505793.001]
  • [Cites] Curr Biol. 2008 Oct 28;18(20):1606-11 [18948007.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Jan;135(1):69-80 [18592271.001]
  • [Cites] Cell Growth Differ. 2000 Jul;11(7):343-54 [10939588.001]
  • (PMID = 19703301.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K99CA127361; United States / NCI NIH HHS / CA / CA030195-22; United States / NCI NIH HHS / CA / R00 CA127361; United States / NCI NIH HHS / CA / P01 CA030195; United States / NCI NIH HHS / CA / K99 CA127361; United States / NCI NIH HHS / CA / R00 CA127361-04; United States / NCI NIH HHS / CA / CA127361-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arhgap5 protein, mouse; 0 / GTPase-Activating Proteins; 0 / Neoplasm Proteins; 0 / Thrombospondin 1; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2750123
  •  go-up   go-down


67. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, Hlatky L, Vajkoczy P, Huber PE, Folkman J, Abdollahi A: Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res; 2009 Feb 1;69(3):836-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype.
  • We have developed models in which human tumors remain dormant for a prolonged period of time (>120 days) until they switch to rapid growth and become strongly angiogenic.
  • These angiogenic tumors retain their ability to grow fast once injected in new mice.
  • We hypothesized that dormant tumors undergo a stable genetic reprogramming during their switch to the fast-growing phenotype.
  • Genome-wide transcriptional analysis was done to dissect the molecular mechanisms underlying the switch of dormant breast carcinoma, glioblastoma, osteosarcoma, and liposarcoma tumors.
  • The switch of dormant tumors was associated with down-regulation of angiogenesis inhibitor thrombospondin and decreased sensitivity of angiogenic tumors to angiostatin.


68. McDonnell K, Bowden ET, Cabal-Manzano R, Hoxter B, Riegel AT, Wellstein A: Vascular leakage in chick embryos after expression of a secreted binding protein for fibroblast growth factors. Lab Invest; 2005 Jun;85(6):747-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secreted FGF-binding proteins (FGF-BPs) can release immobilized FGFs, enhance the activity of locally stored FGFs and can thus serve as an angiogenic switch molecule in cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806140.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA71508
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Fibroblast Growth Factor; 147336-22-9 / Green Fluorescent Proteins; 62031-54-3 / Fibroblast Growth Factors
  •  go-up   go-down


69. Sakao S, Tatsumi K, Voelkel NF: Reversible or irreversible remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol; 2010 Dec;43(6):629-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we ask the question: which forms of pulmonary vascular remodeling are reversible and can such remodeling caused by angiogenic proliferation of EC be reversed?
  • Whereas it is suggested that the proliferative state of SMC may be reversible, it remains unknown whether phenotypically altered EC can switch back to a normal monolayer-forming EC.

  • Genetic Alliance. consumer health - Pulmonary Arterial Hypertension.
  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thromb Haemost. 1997 Jul;78(1):747-54 [9198250.001]
  • [Cites] Am J Pathol. 1997 Oct;151(4):1019-25 [9327735.001]
  • [Cites] Chest. 1998 Sep;114(3 Suppl):213S-224S [9741572.001]
  • [Cites] Pediatr Pulmonol Suppl. 1999;18:194-7 [10093141.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Apr;20(4):582-94 [10100989.001]
  • [Cites] Thorax. 1999 Apr;54(4):372-4 [10092701.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):411-9 [10433934.001]
  • [Cites] J Appl Physiol (1985). 2005 Feb;98(2):722-31 [15501927.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):308-9; author reply 308-9 [15659740.001]
  • [Cites] Circulation. 2005 Feb 8;111(5):534-8 [15699271.001]
  • [Cites] Physiol Rev. 2004 Jul;84(3):767-801 [15269336.001]
  • [Cites] N Engl J Med. 2004 Sep 30;351(14):1425-36 [15459304.001]
  • [Cites] Circ Res. 2004 Oct 15;95(8):830-40 [15375007.001]
  • [Cites] Am J Pathol. 1978 Nov;93(2):353-68 [717535.001]
  • [Cites] Am J Pathol. 1980 Jul;100(1):151-78 [7395963.001]
  • [Cites] Am Rev Respir Dis. 1986 Aug;134(2):342-6 [3740659.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1989 Jan;27(1):51-6 [2501548.001]
  • [Cites] Circulation. 1990 Sep;82(3):841-7 [2394005.001]
  • [Cites] Ann Intern Med. 1991 Mar 15;114(6):464-9 [1994793.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1479-91 [15931388.001]
  • [Cites] FASEB J. 2005 Jul;19(9):1178-80 [15897232.001]
  • [Cites] Circulation. 2005 Jul 19;112(3):423-31 [16027270.001]
  • [Cites] Circulation. 2005 Sep 20;112(12):1806-12 [16157769.001]
  • [Cites] N Engl J Med. 2005 Sep 29;353(13):1412-3 [16192491.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2811-21 [16200212.001]
  • [Cites] Eur Respir J. 2005 Dec;26(6):986-8 [16319325.001]
  • [Cites] Eur Respir J. 2005 Dec;26(6):1110-8 [16319344.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Sep 15;178(6):558-64 [18556624.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2008 Oct;295(4):L648-57 [18708631.001]
  • [Cites] Am J Respir Cell Mol Biol. 2008 Dec;39(6):706-16 [18587055.001]
  • [Cites] Circulation. 2009 Jan 27;119(3):374-81 [19139384.001]
  • [Cites] J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S108-17 [19555854.001]
  • [Cites] Am J Respir Crit Care Med. 2009 Oct 15;180(8):780-7 [19628780.001]
  • [Cites] Eur Respir J. 1999 Dec;14(6):1246-50 [10624750.001]
  • [Cites] Pathol Int. 2000 Jun;50(6):472-9 [10886723.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Dec;162(6):2252-8 [11112148.001]
  • [Cites] FASEB J. 2001 Feb;15(2):427-38 [11156958.001]
  • [Cites] Pediatr Pulmonol. 2006 Feb;41(2):122-5 [16369926.001]
  • [Cites] Respir Res. 2009;10:95 [19825167.001]
  • [Cites] Circulation. 2006 Jun 6;113(22):2630-41 [16735674.001]
  • [Cites] Ann Intern Med. 2006 Jul 18;145(2):152-3 [16847299.001]
  • [Cites] Thorax. 2006 Aug;61(8):736 [16877696.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L294-303 [16980375.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):37-51 [17222789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1342-7 [17227868.001]
  • [Cites] Circulation. 2007 Jan 30;115(4):509-17 [17242277.001]
  • [Cites] J Am Coll Cardiol. 2007 Feb 20;49(7):803-10 [17306711.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11418-23 [17596340.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Jul;293(1):L1-8 [17384082.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L548-54 [17526595.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L583-90 [17586694.001]
  • [Cites] FASEB J. 2007 Sep;21(11):2725-34 [17504974.001]
  • [Cites] FASEB J. 2007 Nov;21(13):3640-52 [17567571.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):361-72 [18227220.001]
  • [Cites] Arthritis Rheum. 2008 Feb;58(2):521-31 [18240255.001]
  • [Cites] Respiration. 2008;75(2):155-7 [17124380.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Feb;163(2):498-502 [11179130.001]
  • [Cites] Circulation. 2001 Aug 14;104(7):790-5 [11502704.001]
  • [Cites] Circ Res. 2001 Sep 14;89(6):517-25 [11557739.001]
  • [Cites] Clin Chest Med. 2001 Sep;22(3):405-18 [11590837.001]
  • [Cites] Pharmacol Ther. 2001 Oct;92(1):1-20 [11750034.001]
  • [Cites] Circulation. 2002 Jan 15;105(2):244-50 [11790708.001]
  • [Cites] N Engl J Med. 2002 Jun 6;346(23):1773-80 [12050336.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Nov 15;166(10):1403-8 [12406854.001]
  • [Cites] Crit Care Med. 2003 Apr;31(4):1213-8 [12682495.001]
  • [Cites] N Engl J Med. 2003 Sep 18;349(12):1113-22 [13679525.001]
  • [Cites] Circulation. 2003 Sep 30;108(13):1640-5 [12963647.001]
  • [Cites] Circ Res. 2004 May 14;94(9):1263-70 [15059929.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2289-97 [15161661.001]
  • [Cites] J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):1S-90S [15194171.001]
  • [Cites] J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):13S-24S [15194174.001]
  • [Cites] Circulation. 1992 Jan;85(1):249-58 [1728456.001]
  • [Cites] Circulation. 1992 Jan;85(1):380-1 [1728476.001]
  • [Cites] N Engl J Med. 1992 Jul 9;327(2):70-5 [1603138.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1732-9 [8497283.001]
  • [Cites] Am J Pathol. 1994 Feb;144(2):275-85 [7508683.001]
  • [Cites] Nature. 1994 Jun 30;369(6483):756-8 [8008069.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7583-7 [7519783.001]
  • [Cites] J Clin Invest. 1995 Jul;96(1):273-81 [7615796.001]
  • [Cites] Chest. 1996 Sep;110(3):710-7 [8797416.001]
  • [Cites] Clin Exp Immunol. 1996 Nov;106(2):389-95 [8918589.001]
  • [Cites] Am J Respir Crit Care Med. 1997 Jan;155(1):274-8 [9001324.001]
  • [Cites] Am J Pathol. 1997 Apr;150(4):1349-60 [9094991.001]
  • (PMID = 20008280.001).
  • [ISSN] 1535-4989
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / 5P01 HL66254-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2993084
  •  go-up   go-down


70. Connor KM, Subbaram S, Regan KJ, Nelson KK, Mazurkiewicz JE, Bartholomew PJ, Aplin AE, Tai YT, Aguirre-Ghiso J, Flores SC, Melendez JA: Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation. J Biol Chem; 2005 Apr 29;280(17):16916-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation.
  • Our findings provide the first evidence for the involvement of mitochondrial H2O2 in regulating PTEN function and the angiogenic switch, indicating that Sod2 can serve as an alternative physiological source of the potent signaling molecule, H2O2.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701646.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI49822; United States / NCI NIH HHS / CA / CA095011; United States / NCI NIH HHS / CA / CA77068
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Fluoresceins; 0 / Phosphatidylinositol Phosphates; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / phosphatidylinositol 3,4,5-triphosphate; 63368-54-7 / 5-iodoacetamidofluorescein; BBX060AN9V / Hydrogen Peroxide; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; EC 1.15.1.1 / superoxide dismutase 2; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; S88TT14065 / Oxygen
  •  go-up   go-down


71. Grinberg S, Hasko G, Wu D, Leibovich SJ: Suppression of PLCbeta2 by endotoxin plays a role in the adenosine A(2A) receptor-mediated switch of macrophages from an inflammatory to an angiogenic phenotype. Am J Pathol; 2009 Dec;175(6):2439-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of PLCbeta2 by endotoxin plays a role in the adenosine A(2A) receptor-mediated switch of macrophages from an inflammatory to an angiogenic phenotype.
  • Toll-like receptor (TLR) 2, 4, 7, and 9 agonists, together with adenosine A(2A) receptor (A(2A)R) agonists, switch macrophages from an inflammatory (M1) to an angiogenic (M2-like) phenotype.
  • This switch involves induction of A(2A)Rs by TLR agonists, down-regulation of tumor necrosis factor alpha (TNFalpha) and interleukin-12, and up-regulation of vascular endothelial growth factor (VEGF) and interleukin-10 expression.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 2003 Sep;306(3):1042-9 [12766259.001]
  • [Cites] Pharmacol Ther. 2003 Nov;100(2):171-94 [14609719.001]
  • [Cites] Trends Immunol. 2004 Jan;25(1):33-9 [14698282.001]
  • [Cites] ScientificWorldJournal. 2004 Jan 16;4:1-8 [14755098.001]
  • [Cites] J Pharmacol Exp Ther. 2004 May;309(2):697-704 [14730005.001]
  • [Cites] Annu Rev Immunol. 1984;2:283-318 [6100475.001]
  • [Cites] J Immunol Methods. 1986 May 22;89(2):271-7 [3486233.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Oct 16;164(1):406-12 [2553017.001]
  • [Cites] J Immunol. 1998 Dec 1;161(11):6206-14 [9834107.001]
  • [Cites] Immunity. 1999 Feb;10(2):137-42 [10072066.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):3005-12 [10072552.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10385-90 [10468617.001]
  • [Cites] Trends Immunol. 2004 Dec;25(12):677-86 [15530839.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2006;46:355-79 [16402909.001]
  • [Cites] J Immunol. 2006 Feb 15;176(4):2414-20 [16456000.001]
  • [Cites] Chem Senses. 2006 Mar;31(3):213-9 [16394244.001]
  • [Cites] Cell Death Differ. 2006 May;13(5):816-25 [16410796.001]
  • [Cites] Arch Pharm Res. 2006 Oct;29(10):890-7 [17121185.001]
  • [Cites] Mol Biol Cell. 2007 Jan;18(1):14-23 [17065555.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jan;1096:1-17 [17405910.001]
  • [Cites] Biochim Biophys Acta. 2007 Jun;1773(6):869-79 [17488650.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2085-9 [17878921.001]
  • [Cites] Immunol Res. 2007;39(1-3):249-60 [17917069.001]
  • [Cites] J Exp Med. 2007 Oct 29;204(11):2719-31 [17954568.001]
  • [Cites] Eur J Immunol. 2007 Nov;37 Suppl 1:S9-17 [17972350.001]
  • [Cites] Biol Res. 2007;40(2):97-112 [18064347.001]
  • [Cites] Immunobiology. 2007;212(9-10):715-22 [18086373.001]
  • [Cites] J Clin Invest. 2008 Jan;118(1):195-204 [18079968.001]
  • [Cites] Curr Protoc Mol Biol. 2007 Apr;Chapter 4:Unit 4.10 [18265405.001]
  • [Cites] Trends Mol Med. 2007 Nov;13(11):460-9 [18029230.001]
  • [Cites] J Leukoc Biol. 2008 Mar;83(3):546-52 [18032691.001]
  • [Cites] Cytokine. 2008 May;42(2):145-51 [18304834.001]
  • [Cites] BMB Rep. 2008 Jun 30;41(6):415-34 [18593525.001]
  • [Cites] Curr Opin Organ Transplant. 2008 Feb;13(1):20-5 [18660702.001]
  • [Cites] Cytokine. 2008 Sep;43(3):342-9 [18706831.001]
  • [Cites] Nat Rev Immunol. 2008 Dec;8(12):958-69 [19029990.001]
  • [Cites] Wound Repair Regen. 2008 Sep-Oct;16(5):585-601 [19128254.001]
  • [Cites] Annu Rev Immunol. 2009;27:451-83 [19105661.001]
  • [Cites] J Leukoc Biol. 2009 Sep;86(3):681-9 [19477908.001]
  • [Cites] Nat Rev Immunol. 2005 Dec;5(12):953-64 [16322748.001]
  • [Cites] Am J Physiol. 1993 Mar;264(3 Pt 1):E465-70 [8384792.001]
  • [Cites] Cell. 1995 Jan 27;80(2):269-78 [7834746.001]
  • [Cites] Microbiol Rev. 1995 Sep;59(3):423-50 [7565413.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1996 May;353(6):599-605 [8738291.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):7971-5 [9223297.001]
  • [Cites] Science. 2000 Feb 11;287(5455):1046-9 [10669417.001]
  • [Cites] Pathobiology. 1999;67(5-6):222-6 [10725788.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6550-5 [10823926.001]
  • [Cites] J Immunol. 2000 Jun 15;164(12):6166-73 [10843666.001]
  • [Cites] J Immunol. 2001 Apr 1;166(7):4713-20 [11254732.001]
  • [Cites] Biochim Biophys Acta. 2001 Jan 15;1530(1):1-14 [11341954.001]
  • [Cites] Adv Enzyme Regul. 2001;41:361-84 [11384755.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7240-7 [11585761.001]
  • [Cites] J Leukoc Biol. 2001 Oct;70(4):478-90 [11590184.001]
  • [Cites] Annu Rev Biochem. 2001;70:281-312 [11395409.001]
  • [Cites] J Immunol. 2002 May 15;168(10):5233-9 [11994480.001]
  • [Cites] Infect Immun. 2002 Jun;70(6):2995-3003 [12010990.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2231-44 [12057925.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):885-91 [12490963.001]
  • [Cites] Nat Rev Immunol. 2003 Jan;3(1):23-35 [12511873.001]
  • [Cites] J Leukoc Biol. 2003 Feb;73(2):209-12 [12554797.001]
  • [Cites] Biochem Soc Trans. 2003 Jun;31(Pt 3):643-7 [12773173.001]
  • [Cites] Exp Biol Med (Maywood). 2003 Jun;228(6):697-705 [12773701.001]
  • [Cites] FEBS Lett. 2003 Jul 3;546(1):25-31 [12829232.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):711-21 [12875990.001]
  • (PMID = 19850892.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL080706-15; United States / NHLBI NIH HHS / HL / R01 HL080706-10; United States / NHLBI NIH HHS / HL / R01 HL080706-12; United States / NHLBI NIH HHS / HL / R01 HL080706; United States / NHLBI NIH HHS / HL / HL080706-13; United States / NHLBI NIH HHS / HL / T32 HL069752; United States / NHLBI NIH HHS / HL / R01 HL080706-13; United States / NHLBI NIH HHS / HL / R01 HL080706-11; United States / NHLBI NIH HHS / HL / 5 T32 HL069752; United States / NIGMS NIH HHS / GM / R01 GM054597; United States / NIGMS NIH HHS / GM / R01GM06836; United States / NHLBI NIH HHS / HL / HL080706-14; United States / NHLBI NIH HHS / HL / R01 HL080706-14
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Lipopolysaccharides; 0 / Myd88 protein, mouse; 0 / Myeloid Differentiation Factor 88; 0 / RNA, Small Interfering; 0 / Receptor, Adenosine A2A; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; EC 3.1.4.11 / Phospholipase C beta; EC 3.1.4.11 / Plcb2 protein, mouse
  • [Other-IDs] NLM/ PMC2789640
  •  go-up   go-down


72. Aurora AB, Biyashev D, Mirochnik Y, Zaichuk TA, Sánchez-Martinez C, Renault MA, Losordo D, Volpert OV: NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement. Blood; 2010 Jul 22;116(3):475-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracellular factors control the angiogenic switch in endothelial cells (ECs) via competing survival and apoptotic pathways.
  • Previously, we showed that proangiogenic and antiangiogenic factors target the same signaling molecules, which thereby become pivots of angiogenic balance.
  • Here we show that in remodeling endothelium (ECs and EC precursors) natural angiogenic inhibitors enhance nuclear factor-kappaB (NF-kappaB) DNA binding, which is critical for antiangiogenesis, and that blocking the NF-kappaB pathway abolishes multiple antiangiogenic events in vitro and in vivo.
  • Our study defines an interactive transcriptional network underlying angiogenic balance and points to HDACi as tools to manipulate the angiogenic switch.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Cycle. 2006 Aug;5(16):1779-87 [16931911.001]
  • [Cites] J Clin Invest. 2006 Nov;116(11):2955-63 [17053836.001]
  • [Cites] Circ Res. 2006 Dec 8;99(12):1347-54 [17082476.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jan;8(1):49-62 [17183360.001]
  • [Cites] Cardiovasc Res. 2007 Nov 1;76(2):195-6 [17936118.001]
  • [Cites] Cell. 2007 Nov 2;131(3):463-75 [17981115.001]
  • [Cites] Cancer Lett. 2009 Aug 8;280(2):160-7 [19342155.001]
  • [Cites] J Physiol Pharmacol. 2009 Jun;60(2):123-31 [19617655.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6343-8 [9600967.001]
  • [Cites] Clin Chem Lab Med. 1998 Aug;36(8):535-9 [9806455.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):2098-108 [10022897.001]
  • [Cites] Mol Cell Biochem. 2004 Oct;265(1-2):171-83 [15543947.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):496-507 [15563312.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):101-11 [15652753.001]
  • [Cites] Curr Oncol Rep. 2005 Mar;7(2):116-22 [15717945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2934-9 [15710885.001]
  • [Cites] Front Biosci. 2005;10:1089-97 [15769608.001]
  • [Cites] Nat Immunol. 2005 May;6(5):439-45 [15843800.001]
  • [Cites] Lymphology. 2005 Mar;38(1):1-8 [15856679.001]
  • [Cites] Genes Dev. 2005 May 1;19(9):1116-27 [15879558.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):649-58 [15818399.001]
  • [Cites] Trends Immunol. 2005 Jun;26(6):318-25 [15922948.001]
  • [Cites] Neuroscience. 2005;133(3):691-700 [15893882.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35 [15961063.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6354-63 [16024638.001]
  • [Cites] J Clin Invest. 2005 Sep;115(9):2382-92 [16100571.001]
  • [Cites] Nat Med. 2005 Sep;11(9):992-7 [16127434.001]
  • [Cites] Nat Rev Immunol. 2005 Oct;5(10):749-59 [16175180.001]
  • [Cites] Cancer Treat Res. 2005;126:103-27 [16209064.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Nov;2(11):562-77 [16270097.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):38-51 [16397526.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 17;340(3):984-94 [16410078.001]
  • [Cites] Cell Death Differ. 2006 May;13(5):693-6 [16485027.001]
  • [Cites] Cancer Treat Rev. 2006 May;32(3):157-65 [16516391.001]
  • [Cites] Circulation. 2006 May 23;113(20):2413-24 [16702471.001]
  • [Cites] Mol Cancer Ther. 2006 Jul;5(7):1693-701 [16891455.001]
  • [Cites] J Biol Chem. 2000 Mar 3;275(9):6421-7 [10692445.001]
  • [Cites] J Biol Chem. 2000 Apr 7;275(14):10023-9 [10744679.001]
  • [Cites] Gene Expr. 1999;8(4):219-29 [10794524.001]
  • [Cites] J Vasc Res. 2000 May-Jun;37(3):209-18 [10859480.001]
  • [Cites] J Exp Med. 2001 Mar 5;193(5):607-20 [11238591.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):409-16 [11283615.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Apr;33(4):391-407 [11312108.001]
  • [Cites] J Cell Physiol. 2001 Aug;188(2):143-60 [11424081.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(16):5299-305 [11463813.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1716-24 [17308113.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):8424-34 [17192276.001]
  • [Cites] J Mol Biol. 2007 Apr 27;368(2):388-97 [17362989.001]
  • [Cites] Radiat Res. 2007 May;167(5):581-91 [17474796.001]
  • [Cites] Biochim Biophys Acta. 2007 Jun;1775(2):298-312 [17572301.001]
  • [Cites] Cardiovasc Res. 2007 Nov 1;76(2):213-23 [17651710.001]
  • [Cites] Int J Cancer. 2001 Sep15;93(6):781-5 [11519037.001]
  • [Cites] Nat Med. 2002 Apr;8(4):349-57 [11927940.001]
  • [Cites] Science. 2002 Nov 8;298(5596):1241-5 [12424381.001]
  • [Cites] Genes Dev. 2003 Sep 15;17(18):2205-32 [12975316.001]
  • [Cites] Arthritis Rheum. 2003 Sep;48(9):2652-9 [13130486.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 24;310(3):804-10 [14550275.001]
  • [Cites] MedGenMed. 2003 Apr 30;5(2):22 [14603121.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):47785-91 [14512418.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jul;36(7):1166-70 [15109564.001]
  • [Cites] J Exp Med. 2004 Jun 7;199(11):1513-22 [15184502.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6626-34 [15374977.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):203-8 [15380510.001]
  • [Cites] Cancer Commun. 1991 Mar;3(3):93-102 [2001331.001]
  • [Cites] Br J Pharmacol. 1997 Dec;122(7):1315-22 [9421277.001]
  • [Cites] Curr Opin Cell Biol. 1998 Apr;10(2):205-19 [9561845.001]
  • [CommentIn] Blood. 2010 Jul 22;116(3):312-3 [20651081.001]
  • [ErratumIn] Blood. 2010 Dec 2;116(23):5079. Aurora, Aryn B [corrected to Aurora, Arin B]
  • (PMID = 20203265.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL068033-07; United States / NHLBI NIH HHS / HL / R01 HL068033-08; United States / NHLBI NIH HHS / HL / HL077471-03; United States / NHLBI NIH HHS / HL / HL077471-04; United States / NHLBI NIH HHS / HL / R01 HL068033; United States / NHLBI NIH HHS / HL / R01 HL057516; United States / NIDDK NIH HHS / DK / T32 DK62716; United States / NHLBI NIH HHS / HL / HL068033-08; United States / NHLBI NIH HHS / HL / R01 HL077471-03; United States / NIDDK NIH HHS / DK / T32 DK062716; United States / NHLBI NIH HHS / HL / R01 HL077471; United States / NHLBI NIH HHS / HL / R01 HL068033-06; United States / NHLBI NIH HHS / HL / R01 HL077471-04; United States / NHLBI NIH HHS / HL / HL068033-06; United States / NHLBI NIH HHS / HL / R01 HL68033; United States / NHLBI NIH HHS / HL / R01 HL068033-07; United States / NHLBI NIH HHS / HL / R01HL077471
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / Cflar protein, mouse; 0 / Eye Proteins; 0 / Fas Ligand Protein; 0 / Fasl protein, mouse; 0 / NF-kappa B; 0 / NFATC Transcription Factors; 0 / Nerve Growth Factors; 0 / Nfatc2 protein, mouse; 0 / Serpins; 0 / Thrombospondin 1; 0 / pigment epithelium-derived factor; EC 3.5.1.98 / Hdac1 protein, mouse; EC 3.5.1.98 / Histone Deacetylase 1
  • [Other-IDs] NLM/ PMC2913457
  •  go-up   go-down


73. Kim MS, Kim YK, Eun HC, Cho KH, Chung JH: All-trans retinoic acid antagonizes UV-induced VEGF production and angiogenesis via the inhibition of ERK activation in human skin keratinocytes. J Invest Dermatol; 2006 Dec;126(12):2697-706
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incident UV radiation leads to the upregulation of vascular endothelial growth factor (VEGF), a potent angiogenic factor, in human skin.
  • Collectively, our data demonstrate that tRA inhibits the UV-induced angiogenic switch via downmodulation of ERK1/2 activation and consecutive VEGF overexpression.


74. Sun ZJ, Zhao YF, Zhao JH: Mast cells in hemangioma: a double-edged sword. Med Hypotheses; 2007;68(4):805-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is evidence that several mast cell mediators are angiogenic by regulating endothelial cell proliferation and degrading the extracellular matrix.
  • It could be postulated that mast cells may play both angiogenic and antiangiogenic roles in different stage of hemangioma.
  • The mast cell secretion may trigger the "angiogenic switch", while the angiogenic roles may function through the other potential angiogenic factors.

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067746.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


75. Zaman K, Driscoll R, Hahn D, Werffeli P, Goodman SL, Bauer J, Leyvraz S, Lejeune F, Stupp R, Rüegg C: Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. Int J Cancer; 2006 Feb 1;118(3):755-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-angiogenic therapies are currently in cancer clinical trials, but to date there are no established tests for evaluating the angiogenic status of a patient.
  • Treatment with chemotherapy and TNF induced changes consistent with an angiogenic switch.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16114015.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Necrosis Factor-alpha; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


76. Fujita M, Khazenzon NM, Bose S, Sekiguchi K, Sasaki T, Carter WG, Ljubimov AV, Black KL, Ljubimova JY: Overexpression of beta1-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases. Breast Cancer Res; 2005;7(4):R411-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously documented a switch in the expression of vascular laminins containing the alpha4 chain from predominantly laminin-9 (alpha4beta2gamma1) to predominantly laminin-8 (alpha4beta1gamma1) during progression of human brain gliomas to high-grade glioblastoma multiforme.
  • Angiogenic switch from laminin-9 and laminin-11 to laminin-8 and laminin-10 first occurs in carcinomas in situ and becomes more pronounced with progression of carcinomas to the invasive stage.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Dyn. 2000 Jun;218(2):213-34 [10842354.001]
  • [Cites] Mol Biol Cell. 2001 Jan;12(1):85-100 [11160825.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Apr;280(4):F695-705 [11249861.001]
  • [Cites] Breast Cancer Res. 2000;2(4):252-7 [11250717.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3741-9 [11325847.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17550-8 [11278628.001]
  • [Cites] J Histochem Cytochem. 2001 Jun;49(6):711-26 [11373318.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5601-10 [11454714.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4457-65 [11494141.001]
  • [Cites] FEBS Lett. 2001 Sep 7;505(1):173-8 [11557064.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1194-202 [11809810.001]
  • [Cites] Br J Cancer. 2002 May 20;86(10):1566-77 [12085206.001]
  • [Cites] Semin Cancer Biol. 2002 Jun;12(3):197-207 [12083850.001]
  • [Cites] Microsc Res Tech. 2003 Jan 1;60(1):107-14 [12500267.001]
  • [Cites] Oncogene. 2003 Apr 10;22(14):2172-85 [12687019.001]
  • [Cites] J Cell Biol. 2003 Apr 14;161(1):197-209 [12695504.001]
  • [Cites] J Invest Dermatol. 1992 Jun;98(6):864-70 [1375618.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):500-7 [1318001.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Lab Invest. 1993 Jan;68(1):100-8 [7678659.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] J Pathol. 2003 Jul;200(4):465-70 [12845613.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):821-39 [12875598.001]
  • [Cites] J Pathol. 2003 Oct;201(2):173-80 [14517833.001]
  • [Cites] Mol Cancer Ther. 2003 Oct;2(10):985-94 [14578463.001]
  • [Cites] Clin Exp Metastasis. 2003;20(6):569-76 [14598892.001]
  • [Cites] Biomed Pharmacother. 2003 Dec;57(10):463-70 [14637390.001]
  • [Cites] Pathol Int. 2004 Jan;54(1):10-5 [14674989.001]
  • [Cites] Exp Cell Res. 2004 Jan 1;292(1):67-77 [14720507.001]
  • [Cites] J Mol Diagn. 2004 Feb;6(1):10-5 [14736821.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2343-6 [15059883.001]
  • [Cites] J Natl Cancer Inst. 2004 May 19;96(10):759-69 [15150304.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] Cancer Lett. 2004 Jul 16;210(2):239-44 [15183540.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):604-12 [15274074.001]
  • [Cites] J Cell Sci. 2004 Sep 1;117(Pt 19):4481-94 [15316072.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:255-84 [15473841.001]
  • [Cites] Neuro Oncol. 2004 Oct;6(4):281-9 [15494095.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Cell Regul. 1990 Sep;1(10):731-40 [2099832.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):562-6 [1371500.001]
  • [Cites] Breast Cancer Res Treat. 1999 Oct;57(3):237-43 [10617300.001]
  • [Cites] JAMA. 2000 Jan 26;283(4):453-5 [10659859.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):615-24 [10662785.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):269-77 [8425764.001]
  • [Cites] J Pathol. 1997 Feb;181(2):207-12 [9120727.001]
  • [Cites] J Cell Biol. 1997 May 5;137(3):685-701 [9151674.001]
  • [Cites] J Biol Chem. 1997 Nov 7;272(45):28590-5 [9353324.001]
  • [Cites] Dev Dyn. 1997 Dec;210(4):446-62 [9415429.001]
  • [Cites] Exp Cell Res. 1997 Nov 25;237(1):70-6 [9417868.001]
  • [Cites] Annu Rev Med. 1998;49:407-24 [9509272.001]
  • [Cites] FEBS Lett. 1998 Jul 3;430(3):217-21 [9688542.001]
  • [Cites] Virchows Arch. 1999 Apr;434(4):325-32 [10335943.001]
  • [CommentIn] Breast Cancer Res. 2005;7(4):166-7 [15987470.001]
  • (PMID = 15987446.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / N01-HD-2-3144
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Laminin; 0 / Protein Isoforms; 0 / laminin 10; 0 / laminin 8; 0 / laminin 9
  • [Other-IDs] NLM/ PMC1175051
  •  go-up   go-down


77. Hamlat A, Adn M, Pasqualini E, Brassier G, Askar B: Pathophysiology of capillary haemangioma growth after birth. Med Hypotheses; 2005;64(6):1093-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In newborn infants with haemangioma, persistent embryonic primitive endothelial cells trapped in the intimae underneath the developing vessels, and representing "leader" endothelial cells, can stabilise the labile vascular endothelial growth factor mRNA (VEGF mRNA), produce other angiogenic factors, degrade the underlying basement membrane and invade into the stroma of the neighbouring tissue.
  • Consequently, in babies with haemangioma, hypoxia can act as a switch to activate these "leader" endothelial cells and thereby initiate a cascade of reactions leading to CH proliferation.
  • Addressing this mechanism in vivo has partly been done (the angiogenic peptide bFGF varies with haemangioma growth).
  • [MeSH-minor] Adult. Angiogenesis Inhibitors / pharmacology. Angiogenesis Inhibitors / therapeutic use. Angiogenic Proteins / biosynthesis. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Lineage. Female. Fetus / metabolism. Humans. Infant. Infant, Newborn. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823691.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Angiogenic Proteins; 0 / Antineoplastic Agents
  •  go-up   go-down


78. Ghosh M, Ai Y, Narko K, Wang Z, Peters JM, Hla T: PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer. Prostaglandins Other Lipid Mediat; 2009 Apr;88(3-4):97-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously, we showed that COX-2 over-expression in the mammary gland of transgenic mice induces an angiogenic switch and transforms the mammary epithelium into invasive mammary carcinoma.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13275-80 [11087869.001]
  • [Cites] Cell. 1999 Oct 29;99(3):335-45 [10555149.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18563-9 [11278747.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):632-5 [11830510.001]
  • [Cites] Prostate. 2002 Nov 1;53(3):232-40 [12386924.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6846-9 [12460897.001]
  • [Cites] J Cell Mol Med. 2003 Jul-Sep;7(3):207-22 [14594546.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):591-6 [14688410.001]
  • [Cites] Ann N Y Acad Sci. 1999;889:84-6 [10668485.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5119-28 [10866668.001]
  • [Cites] Nat Med. 2004 Mar;10(3):245-7 [14758356.001]
  • [Cites] Nat Med. 2004 May;10(5):481-3 [15048110.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3162-70 [15126355.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23719-27 [15033975.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2556-60 [8653697.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1561-74 [10385625.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2018-24 [10473081.001]
  • [Cites] Oncogene. 2004 Nov 25;23(55):8992-6 [15480419.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4496-9 [15930264.001]
  • [Cites] Cell Signal. 2006 Jan;18(1):9-20 [16109478.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 10;340(2):656-60 [16378595.001]
  • [Cites] Toxicol Sci. 2006 Apr;90(2):269-95 [16322072.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4394-401 [16618765.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4245-54 [17201140.001]
  • [Cites] Int J Oncol. 2007 Sep;31(3):607-11 [17671688.001]
  • [Cites] J Exp Med. 2007 Sep 3;204(9):2053-61 [17724132.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2641-9 [17693664.001]
  • [Cites] Breast Cancer Res. 2007;9(4):210 [17640394.001]
  • [Cites] Carcinogenesis. 2008 Jan;29(1):169-76 [17893232.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):558-61 [11297248.001]
  • (PMID = 19101649.001).
  • [ISSN] 1098-8823
  • [Journal-full-title] Prostaglandins & other lipid mediators
  • [ISO-abbreviation] Prostaglandins Other Lipid Mediat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA095181-05; United States / NCI NIH HHS / CA / R01 CA095181-05; United States / NCI NIH HHS / CA / P01 CA077839; United States / NCI NIH HHS / CA / P01 CA077839-090007; United States / NCI NIH HHS / CA / CA077839-090007; United States / NCI NIH HHS / CA / R01 CA095181
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 0 / Ki-67 Antigen; 0 / Mki67 protein, mouse; 0 / PPAR delta; 0 / Prostaglandins; 136601-57-5 / Cyclin D1; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ NIHMS93342; NLM/ PMC2662999
  •  go-up   go-down


79. Bulnes S, Lafuente JV: VEGF immunopositivity related to malignancy degree, proliferative activity and angiogenesis in ENU-induced gliomas. J Mol Neurosci; 2007;33(2):163-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During tumor development, neoplastic cells switch to an angiogenic phenotype, playing a significant role in the expression of the vascular endothelial growth factor (VEGF).
  • To identify the "angiogenic switch," we propose the glioma stage characterized by VEGF immunopositive neoplastic cells inside the tumor and positive endothelial cells surrounding it.

  • Hazardous Substances Data Bank. N-NITROSO-N-ETHYLUREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917075.001).
  • [ISSN] 0895-8696
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Vascular Endothelial Growth Factor A; P8M1T4190R / Ethylnitrosourea
  •  go-up   go-down


80. Larghero P, Venè R, Minghelli S, Travaini G, Morini M, Ferrari N, Pfeffer U, Noonan DM, Albini A, Benelli R: Biological assays and genomic analysis reveal lipoic acid modulation of endothelial cell behavior and gene expression. Carcinogenesis; 2007 May;28(5):1008-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The long-term gene regulation (48 h and 4 days) shows higher rates of modulation as compared with the array data, confirming that LA is able to switch the regulation of several genes linked to cell survival, inflammation and oxidative stress.
  • LA induced the production of tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) in KS-Imm and activin-A in KS-Imm and endothelial cells; these factors show anti-angiogenic activity in vivo contributing to explain the inhibitory effect of LA on neovascularization.
  • According to our data, LA has promising anti-angiogenic properties, though its influence on central metabolic pathways should suggest more caution about its widespread and not prescribed use at pharmacological doses.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127716.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 73Y7P0K73Y / Thioctic Acid
  •  go-up   go-down


81. Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, Lim ST, Bernard-Trifilo JA, Ilic D, Stupack DG, Cheresh DA, Schlaepfer DD: Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene; 2006 Sep 28;25(44):5969-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors.
  • These studies provide the first biological support for Y925 FAK phosphorylation and define a novel role for FAK activity in promoting a MAPK-associated angiogenic switch during tumor progression.


82. Hasina R, Pontier AL, Fekete MJ, Martin LE, Qi XM, Brigaudeau C, Pramanik R, Cline EI, Coignet LJ, Lingen MW: NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype. Oncogene; 2006 Jan 26;25(4):588-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype.
  • The induction of tumor dormancy correlated with an angiogenic switch caused by a decreased production of vascular endothelial growth factor and an increase in the production of the angiogenesis inhibitor thrombospondin-1.
  • These data suggest that NOL7 may function as a TSG in part by modulating the expression of the angiogenic phenotype.


83. Noonan DM, Benelli R, Albini A: Angiogenesis and cancer prevention: a vision. Recent Results Cancer Res; 2007;174:219-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We noted that angiogenesis is a common and key target of most chemopreventive molecules, where they most likely suppress the angiogenic switch in premalignant tumors, a concept we termed angioprevention.
  • N-acetyl-cysteine, and the green tea flavonoid epigallocatechin-3-gallate (EGCG) and the beer/ hops-derived chalcone Xanthohumol all prevent angiogenesis in the Matrigel sponge angiogenic assay in vivo and inhibit the growth of the highly angiogenic Kaposi's sarcoma tumor cells (KS-Imm) in nude mice.
  • The synthetic retinoid 4-hydroxyfenretinide (4HPR) also shows anti-angiogenic effects.
  • In contrast, the ROS-producing 4HPR induced members of the TGFbeta-ligand superfamily, which, at least in part, explains its anti-angiogenic activity.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302199.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents
  • [Number-of-references] 31
  •  go-up   go-down


84. Chen W, Li F, Mead L, White H, Walker J, Ingram DA, Roman A: Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior. Virology; 2007 Oct 10;367(1):168-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior.
  • We have previously reported that expression of human papillomavirus type 16 E6 and E7 (HPV16 E6E7) proteins in primary foreskin keratinocytes (HFKs) decreases expression of two inhibitors and increases expression of two angiogenic inducers [Toussaint-Smith, E., Donner, D.B., Roman, A., 2004.
  • Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors.
  • In addition, introduction of the conditioned media into immunocompetent mice using a Matrigel plug model resulted in a clear angiogenic response.
  • These novel data support the hypothesis that HPV proteins contribute not only to the uncontrolled keratinocyte growth seen following HPV infection but also to the angiogenic response needed for tumor formation.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] Virology. 2006 Dec 5-20;356(1-2):68-78 [16945398.001]
  • [Cites] J Virol. 2001 May;75(9):4283-96 [11287578.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] J Virol. 2002 Sep;76(17):8710-21 [12163591.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):6041-8 [12203116.001]
  • [Cites] Virology. 2002 Sep 30;301(2):247-54 [12359427.001]
  • [Cites] J Virol. 2003 Jan;77(2):1551-63 [12502868.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] J Virol. 2003 May;77(10):6066-9 [12719599.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5938-45 [12955072.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1772-83 [14652239.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):2988-95 [14968115.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6482-8 [15374958.001]
  • [Cites] Cell. 1982 Dec;31(3 Pt 2):693-703 [6186388.001]
  • [Cites] J Natl Cancer Inst. 1995 Aug 16;87(16):1237-45 [7563170.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):247-58 [8686749.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Adv Cancer Res. 1996;69:135-74 [8791681.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1847-57 [8934530.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1294-300 [9102216.001]
  • [Cites] Br J Cancer. 1997;76(11):1410-5 [9400935.001]
  • [Cites] Laryngoscope. 1998 Jul;108(7):1098-103 [9665264.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):485-9 [10448304.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Hum Mol Genet. 2006 Jun 1;15(11):1858-69 [16648142.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Oct 14;277(1):55-61 [11027639.001]
  • (PMID = 17602722.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] ENG
  • [Grant] United States / PHS HHS / / NF043019; United States / NCI NIH HHS / CA / T32 CA111198; United States / NCI NIH HHS / CA / CA111198-02S1; United States / NCI NIH HHS / CA / T32 CA11 1198-02S1; United States / NCI NIH HHS / CA / P30 CA082709; United States / NINDS NIH HHS / NS / P50 NS0 52606; United States / NCI NIH HHS / CA / K08 CA096579-01; United States / NCI NIH HHS / CA / P30 CA82709; United States / NCI NIH HHS / CA / T32 CA111198-02S1; United States / NCI NIH HHS / CA / K08 CA096579; United States / NIAID NIH HHS / AI / U19 AI031494; United States / NIAID NIH HHS / AI / U19 AI031494-130005; United States / NIAID NIH HHS / AI / AI031494-130005; United States / NINDS NIH HHS / NS / P50 NS052606; United States / NIAID NIH HHS / AI / R01AI31494
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Repressor Proteins; 0 / oncogene protein E7, Human papillomavirus type 16
  • [Other-IDs] NLM/ NIHMS31797; NLM/ PMC2043482
  •  go-up   go-down


86. Sharma-Walia N, Raghu H, Sadagopan S, Sivakumar R, Veettil MV, Naranatt PP, Smith MM, Chandran B: Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression. J Virol; 2006 Jul;80(13):6534-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KSHV infection is characterized by the induction of preexisting host signal cascades; sustained expression of the latency-associated open reading frame 73 (ORF73) (LANA-1), ORF72, and K13 genes; transient expression of a limited number of lytic genes, including the lytic cycle switch ORF50 (replication and transcription activator) gene; and reprogramming of host transcriptional machinery regulating a variety of cellular processes, including several proinflammatory responses.
  • Since COX-2 is an important mediator of inflammatory and angiogenic responses, here, using real-time PCR, Western blot, and immunofluorescence assays, we characterized the COX-2 stimulation and its role in KSHV infection.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. INDOMETHACIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Jan 1;64(1):72-84 [14729610.001]
  • [Cites] Viral Immunol. 2003;16(4):447-60 [14733733.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1632-4 [14615380.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 4;1654(1):51-67 [14984767.001]
  • [Cites] J Virol. 2004 Apr;78(7):3489-501 [15016872.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] J Virol. 2004 Apr;78(8):4207-23 [15047836.001]
  • [Cites] Br J Dermatol. 1990 Sep;123(3):375-80 [2119789.001]
  • [Cites] Antiviral Res. 1990 Sep;14(3):161-72 [1964373.001]
  • [Cites] Res Immunol. 1992 Jan;143(1):65-70 [1314406.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7384-8 [1380156.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1992 Nov;78(2):249-52 [1335594.001]
  • [Cites] J Gen Virol. 1993 Sep;74 ( Pt 9):1951-4 [8397285.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):24965-71 [7559624.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Sep;281(3):L537-43 [11504678.001]
  • [Cites] Int J Cancer. 2001 Dec 15;94(6):813-9 [11745483.001]
  • [Cites] J Virol. 2002 Mar;76(5):2440-8 [11836422.001]
  • [Cites] Cell. 2002 Feb 8;108(3):407-19 [11853674.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Feb;16(2):251-60 [11860408.001]
  • [Cites] Virus Res. 2002 Jan 30;82(1-2):115-26 [11885938.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3932-7 [11867761.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2522-30 [11980644.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):373-82 [12044013.001]
  • [Cites] Arch Virol. 2002 Jul;147(7):1349-70 [12111412.001]
  • [Cites] J Gen Virol. 2002 Aug;83(Pt 8):1897-905 [12124453.001]
  • [Cites] Blood. 2002 Aug 1;100(3):888-96 [12130499.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30665-74 [12068008.001]
  • [Cites] Clin Exp Immunol. 2002 Sep;129(3):438-45 [12197884.001]
  • [Cites] J Clin Invest. 2002 Dec;110(12):1831-8 [12488433.001]
  • [Cites] J Virol. 2003 Jan;77(2):1524-39 [12502866.001]
  • [Cites] J Virol. 2003 Mar;77(5):3131-47 [12584338.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] J Virol. 2005 Feb;79(3):1397-408 [15650166.001]
  • [Cites] J Virol. 2005 Jun;79(12):7453-65 [15919901.001]
  • [Cites] J Virol. 2005 Jul;79(13):8493-505 [15956592.001]
  • [Cites] J Virol. 2005 Aug;79(16):10308-29 [16051824.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Jul;2(7):370-5; quiz 376 [16075797.001]
  • [Cites] Microsc Res Tech. 2005 Nov;68(3-4):120-9 [16276519.001]
  • [Cites] Gut. 2006 Jan;55(1):115-22 [16118353.001]
  • [Cites] J Viral Hepat. 1999 Jul;6(4):329-36 [10607248.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7908-16 [10630643.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] J Virol. 1997 Jun;71(6):4187-92 [9151804.001]
  • [Cites] Cell. 1997 Oct 17;91(2):157-60 [9346233.001]
  • [Cites] Exp Lung Res. 1998 Jan-Feb;24(1):3-14 [9457465.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] Blood. 1998 Jul 1;92(1):40-5 [9639497.001]
  • [Cites] J Neurosci. 1998 Aug 15;18(16):6279-89 [9698320.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] Nature. 1998 Sep 17;395(6699):281-4 [9751056.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27306-14 [9765256.001]
  • [Cites] Inflamm Res. 1998 Oct;47 Suppl 2:S78-87 [9831328.001]
  • [Cites] J Virol. 1999 Feb;73(2):1438-46 [9882349.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] J Virol. 1999 Aug;73(8):6892-902 [10400787.001]
  • [Cites] Virology. 1999 Sep 15;262(1):237-49 [10489357.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2005 Jan;79(2):1191-206 [15613346.001]
  • [Cites] AIDS. 2000 Jun 16;14(9):1123-33 [10894276.001]
  • [Cites] Annu Rev Biochem. 2000;69:145-82 [10966456.001]
  • [Cites] Virology. 2000 Oct 10;276(1):44-51 [11021993.001]
  • [Cites] J Virol. 2001 Jan;75(1):192-8 [11119588.001]
  • [Cites] J Virol. 2001 Feb;75(3):1378-86 [11152511.001]
  • [Cites] J Virol. 2001 Feb;75(4):1798-807 [11160678.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2720-6 [11289153.001]
  • [Cites] Virology. 2001 Apr 10;282(2):245-55 [11289807.001]
  • [Cites] Virology. 2001 Jun 5;284(2):235-49 [11384223.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6905-10 [11381123.001]
  • [Cites] J Virol. 2001 Aug;75(16):7517-27 [11462024.001]
  • [Cites] J Virol. 2000 Jun;74(12):5740-5 [10823885.001]
  • [Cites] J Virol. 2003 Jul;77(14):7978-90 [12829837.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5150-63 [12910252.001]
  • [Cites] J Virol. 2003 Sep;77(17):9669-84 [12915579.001]
  • [Cites] J Virol. 2003 Sep;77(18):9738-49 [12941882.001]
  • [Cites] J Virol. 2003 Dec;77(23):12753-63 [14610197.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):431-6 [14706335.001]
  • (PMID = 16775340.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075911; United States / NCI NIH HHS / CA / R01 CA099925; United States / NCI NIH HHS / CA / CA 099925; United States / NCI NIH HHS / CA / CA 75911
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Membrane Proteins; 0 / Nitrobenzenes; 0 / Sulfonamides; 0 / Viral Envelope Proteins; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS1 protein, human; EC 1.14.99.1 / PTGS2 protein, human; K7Q1JQR04M / Dinoprostone; XXE1CET956 / Indomethacin
  • [Other-IDs] NLM/ PMC1488986
  •  go-up   go-down


87. Akeson A, Herman A, Wiginton D, Greenberg J: Endothelial cell activation in a VEGF-A gradient: relevance to cell fate decisions. Microvasc Res; 2010 Jul;80(1):65-74
PDF icon [Fulltext service] Download